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ABSTRACT 
 
Nadya Maria Belenky: Effects of Medicare Part D on Medicaid-Medicare Dual Eligibles with HIV 
(Under the direction of Brian Pence) 
The goal of this dissertation was to estimate the effects of Medicare Part D implementation 
on a range of outcomes in Medicaid-Medicare dual eligibles with HIV. Dual eligibles receive primary 
coverage from Medicare, while Medicaid provides wrap-around support, both financially and by 
covering services not included in Medicare coverage. When Medicare Part D was implemented in 
2006, Medicaid-Medicare dual eligibles with HIV lost their prescription drug coverage through 
Medicaid and were auto-enrolled into a Medicare Part D prescription drug plan. Despite benefits to 
most Medicare enrollees, there were indications that, for dual eligibles, Medicare Part D was 
associated with mandated cost-sharing and other barriers to medication access. Using 2003-2008 
data from the Women’s Interagency HIV Study, we created a propensity score matched cohort and 
used a difference-in-differences approach to compare dual eligibles’ outcomes pre- and post-
Medicare Part D to those enrolled in Medicaid alone.  
The transition to Medicare Part D was associated with a sharp increase in the proportion of 
dual eligibles with self-reported out-of-pocket prescription drug costs, followed by a more gradual 
increase in the proportion of dual eligibles using AIDS Drug Assistance Programs (ADAP). Even 
though Medicare Part D was associated with increased out-of-pocket spending, that increase did not 
appear to compromise antiretroviral therapy (ART) adherence or antidepressant use. Further, HIV 
viral load suppression, depressive symptoms, and hospitalization remained stable after Medicare Part 
D implementation. It is possible that co-occurring increased ADAP use mitigated the increase in out-
of-pocket spending, pointing to successful coordination between Medicare Part D and ADAP as well 
as the vital role of ADAP during insurance transitions for this vulnerable population. These results 
may also signal that Medicare Part D’s designation of ART and antidepressants as protected drug 
classes had its intended effect.  
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CHAPTER 1. INTRODUCTION 
Overview and Specific Aims 
Medicare Part D was designed to improve medication access by reducing financial barriers 
for Medicare enrollees, many of whom did not have prescription drug coverage. A subset of Medicare 
enrollees receive a combination of Medicare and Medicaid benefits, and are referred to as “dual 
eligible.” The goal of this dissertation is to estimate the effects of Medicare Part D implementation on 
various outcomes in dual eligibles infected with the human immunodeficiency virus (HIV). The 
implementation of Medicare Part D, Medicare’s prescription drug benefit, may have affected how dual 
eligibles with HIV access antiretroviral therapy (ART) and other prescription drugs and, consequently, 
their medication use and health outcomes. Little is known about the effects of Medicare Part D on 
people with HIV, where the existing studies indicated disruptive effects of Medicare Part D in people 
with HIV. The rationale for the particularly disruptive effect in this population is based on the 
demographic and clinical characteristics of dual eligibles with HIV, their prior coverage through 
Medicaid, and unique rules for how Medicare Part D was applied to dual eligibles.  
Medicare and Medicaid are crucial to accessing HIV care and treatment because these 
programs provide insurance coverage to 56% of adults with HIV in the United States.
1
 Although the 
two programs have different eligibility criteria and distinct application processes, 10% of people with 
HIV simultaneously meet the eligibility requirements for both Medicaid and Medicare and are enrolled 
in both programs.
2
 These individuals receive a combination of Medicaid and Medicare benefits and 
are referred to as “dual eligible.” For dual eligibles, Medicare provides primary coverage, with 
secondary coverage through Medicaid when Medicare benefits are exhausted.
3
 Crucially, Medicaid 
can also serve as the primary coverage source for services not covered by Medicare.
4,5
  
 Before 2006, Medicare did not include a prescription drug benefit and dual eligibles received 
prescription drug coverage through Medicaid. On January 1, 2006, Medicare implemented Medicare 
Part D, its first prescription drug benefit. In an attempt to safeguard against coverage interruptions in 
2 
its most vulnerable population, the Centers for Medicare and Medicaid Services (CMS) auto-enrolled 
dual eligibles into Medicare Part D prescription drug plans, replacing their drug coverage through 
Medicaid.
6
 Despite special protections for the medically and financially disadvantaged, the transition 
to Medicare Part D exposed dual eligibles to changes in payment systems, plan instability, and 
variation in drug plan formularies and was associated with coverage gaps and treatment interruption 
in vulnerable populations.
7
 One early survey reported that 20% of dual eligibles had difficulties filling 
prescriptions after the transition.
8
 Cross-sectional research on a small number of people living with 
HIV who were covered by Medicare Part D showed an association between the transition and ART 
interruption.
9
 These initial findings are supported by reports from HIV providers that the majority of 
their patients had difficulties accessing their prescriptions drugs under Medicare Part D.
10
  
Treatment interruption may be particularly problematic for dual eligibles with HIV because of 
complex medication regimens needed to manage both HIV and common co-morbidities such as 
depressive symptoms. Dual eligibles with HIV depend on consistent ART access to maintain viral 
load (VL) suppression and protect against HIV-related morbidity and mortality.
11
 Depression, a 
common psychiatric comorbidity, has been associated with shortened survival time in individuals with 
HIV,
12
 and untreated depression has been associated with decreased ART adherence and 
unsuppressed VL.
13
 Despite Medicare Part D's direct and ongoing impact on medication access,
14
 the 
effects of Medicare Part D implementation are not well understood in dual eligibles with HIV. 
This study estimated the effects of the transition to Medicare Part D in dual eligible women 
with HIV. Data from the Women's Interagency HIV Study (WIHS) were used to estimate changes in 
out-of-pocket costs, medication access, ART and antidepressant medication use as well as related 
health outcomes and hospitalization associated with the transition to Medicare Part D. 
Aim 1: Estimate the effect of the Medicare Part D transition on out-of-pocket prescription drug 
spending, AIDS Drug Assistance Programs (ADAP) use, ART adherence, and HIV VL 
suppression in dual eligibles with HIV. 
Hypothesis: The transition to Medicare Part D would be associated with increased out-of-
pocket (OOP) prescription drug spending, increased ADAP use, reduced ART adherence, and less 
HIV VL suppression among dual eligibles, after adjusting for temporal trends. 
3 
Rationale: The implementation of Medicare Part D in 2006 exposed dual eligibles to changing 
plan requirements, formulary variation, and loss of Medicaid prescription drug benefit protections. If 
coverage changes result in increased OOP costs and present barriers to optimal medication use, 
OOP spending for prescription drugs and ART nonadherence are expected to be greater after 
Medicare Part D implementation. Following changes in OOP spending, ADAP use is expected to 
increase to relieve the increased financial burden, and HIV VL suppression is expected to decrease, 
due to greater ART nonadherence.  
Aim 2: Estimate the effect of Medicare Part D on antidepressant use, depressive symptoms, 
and hospitalization. 
Hypothesis: Medicare Part D implementation would be associated with decreased 
antidepressant use, higher depressive symptom scores, and increased hospitalization. 
Rationale: Medicare Part D implementation is expected to result in decreased antidepressant 
use after 2006. That shift is expected to lead to increased depressive symptoms and hospitalization, 
mediated through reduced antidepressant medication use. 
Structure of Dissertation 
This dissertation consists of two discrete papers, corresponding to the two specific aims. 
Chapter 2 presents the background, rationale, and policy implications of this study. Chapter 3 outlines 
the analytic methods common to both aims. Chapters 4 and 5 summarize Aims 1 and 2, respectively. 
Chapter 4 (Aim 1) presents results of Medicare Part D’s effect on OOP prescription drug spending, 
ADAP use, ART adherence, and HIV VL suppression. Chapter 5 (Aim 2) examines Medicare Part D’s 
effect on depression-related outcomes, including hospitalization. Chapter 6 discusses and interprets 
those results, concluding with policy implications and future research directions.   
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CHAPTER 2: BACKGROUND 
This chapter begins with a review of HIV and HIV treatment and outlines common pathways 
through which people with HIV access prescription drugs as well as how prescription drug coverage 
affects people with HIV. It includes a section on the provisions and application of Medicare Part D and 
a literature review of relevant Medicare Part D studies. The chapter also reviews the characteristics of 
Medicaid prescription drug benefits prior to Medicare Part D implementation and the federal safety-
net programs for prescription drug provision, the AIDS Drug Assistance Programs (ADAP). Finally, 
this chapter discusses this study’s contribution to the literature and policy implications and ends with 
an overview of the following dissertation chapters.  
HIV/AIDS 
HIV damages the body’s immune system, impeding an individual’s ability to ward off infection. 
When the immune system is weakened, individuals become vulnerable to opportunistic infections, 
which cause HIV-related morbidity and mortality. Although HIV is incurable, treatment advances in 
ART have led to significant reductions in HIV-related illness and mortality.
15
 In addition to clinical 
benefits, consistent ART use has led to significant reductions in HIV transmission.
15
 Advances in the 
effectiveness of ART have resulted in a shift toward treating HIV as a chronic condition that can be 
managed with consistent and adequate access to treatment. These findings highlight the importance 
of consistent ART use (and access) for individuals living with HIV as well as for the HIV-uninfected 
population. These findings are also the foundation for the test-and-treat model, which posits that early 
identification of HIV infection followed by  immediate initiation and consistent use of ART could lead to 
dramatic reductions in the incidence of HIV.
16
 Despite effective treatment, access remains a 
significant barrier for people living with HIV, and within the United States it is estimated that >80% of 
people with HIV have detectable VLs.
17,18
  
In addition to HIV treatment, people with HIV have a high prevalence of co-morbidities that 
can affect quality of life and HIV-related health outcomes. Depression is the most common psychiatric 
5 
comorbidity in people with HIV.
19
 Untreated depressive symptoms have been associated with 
reduced ART adherence,
12,13,20
 unsuppressed HIV VL,
21,22
 and shortened survival time.
23
 By contrast, 
people with HIV who are treated for depression showed similar ART adherence and viral control as 
people with HIV who did not have depression,
24
 underscoring the importance of consistent access to 
antidepressants in this population.  
Pathways to Prescription Drug Access for People with HIV 
For many people with HIV, health insurance provides coverage for prescription drugs that 
would be prohibitively expensive otherwise.
25
 The majority of people with HIV in the United States rely 
on public insurance programs for medication access, with 56% receiving coverage through Medicaid 
or Medicare.
1
 Medicaid is a state-administered program designed for certain categorically eligible low-
income U.S. citizens. To qualify, individuals must meet financial eligibility criteria and be “categorically 
eligible” (e.g., have a documented disability).
5
 Separately, individuals become eligible for Medicare, a 
federally-administered program once they reach age 65 or, if under age 65, by having a permanent 
disability that qualifies them for Social Security Disability Insurance.
3
 People with HIV can be 
categorically eligible for Medicaid by having dependent children or receiving Supplemental Security 
Income because of documented disability. Among people with HIV who are enrolled in Medicaid or 
Medicare, 10% meet the eligibility requirements for both Medicaid and Medicare and receive joint 
coverage (these individuals are referred to as "dual eligibles").
2
  
AIDS Drug Assistance Programs  
AIDS Drug Assistance Programs (ADAPs) function as a safety net for prescription drugs and 
are intended to improve medication access for low-income, uninsured, and underinsured people with 
HIV.
26
 ADAPs are federally funded but administered at the state level, and ADAPs vary state-by-state 
in available ADAP funding and program scope. Although all ADAPs are federally funded through the 
Ryan White HIV/AIDS Program, some ADAPs receive additional state funds, further adding to state-
by-state variation. Within states, ADAPs are able to determine the scope of the services provided, 
and states determine their own ADAP drug formularies and financial eligibility criteria. All ADAP 
formularies include ART but may also include medications to treat other co-morbidities, such as 
6 
cardiovascular disease, opportunistic infections, or psychiatric conditions. ADAP enrollment has been 
shown to affect ART use as well as the use of medications to treat common co-morbidities.
27
  
Effects of insurance and coverage characteristics  
Even though health insurance facilitates access to health services by reducing financial 
barriers, leading to better health outcomes compared to those without coverage,
28,29
 it does not 
guarantee access. Coverage may be attached to prohibitive cost-sharing requirements, utilization 
management tools, or other characteristics that create barriers to health services.  
Cost-sharing is the amount individuals pay for items or services covered by their health 
insurance (e.g., hospital stay, physician visit, or prescription drugs). A systematic review of cost-
sharing literature indicated that for every 10% increase in cost-sharing there was a 2–6% decrease in 
prescription drug use.
30
 In another systematic review on the relationship between other formulary 
restrictions and medication adherence, 68% of studies found that formulary restrictions were 
negatively associated with adherence.
31
 The majority of reviewed studies (60%) focused on cost-
sharing compared to a small number of studies that focused on clinical outcomes (4%), highlighting 
the lack of research on the effects of formulary restrictions on health outcomes.
32,33
   
Medicaid-Medicare Dual Eligibility 
Dual eligibles are unique among the publicly insured because they receive patchwork 
coverage through Medicaid and Medicare. Medicare provides primary coverage for dual eligibles, 
followed by secondary, wrap-around Medicaid coverage when Medicare benefits are exhausted.
4
 In 
practice, Medicare covers the majority of services for dual eligibles and Medicaid absorbs residual 
Medicare costs (e.g., insurance premiums). Crucially, Medicaid can also provide coverage for 
services that are not available through Medicare but still vital to people with HIV, such as long-term 
care and, before 2006, prescription drug coverage.
5
 
Dual eligibles' prescription drug coverage has been a historical exception to Medicare's role 
as a primary coverage source. Before 2006, Medicare coverage did not include a prescription drug 
benefit and, consequently, dual eligibles received prescription drugs through their Medicaid benefits. 
On January 1, 2006, the Medicare Modernization Act introduced Medicare Part D, Medicare's first 
prescription drug benefit. In an attempt to safeguard against coverage interruptions in its most 
7 
vulnerable population, the CMS auto-enrolled dual eligibles into Medicare Part D prescription drug 
plans, replacing their drug coverage through Medicaid with randomly selected Part D drug plans 
known as “benchmark plans.”
6
 Even though Medicare Part D premiums were fully subsidized and 
cost-sharing was minimal for dual eligibles, the transition exposed them to changes in payment 
systems, formulary variation, and plan instability.
34
 After initial random assignment to new prescription 
drug plans at Medicare Part D implementation, dual eligibles continue to be exposed to automatic, 
random re-assignment if their previous prescription drug plan does not continue to meet benchmark 
plan requirements.
35
 Re-assignment can result in coverage disruption if the new prescription drug 
plan has substantially different coverage or requirements.  
Dual eligibles are uniquely vulnerable to coverage disruptions because of their low income 
and are particularly susceptible to negative consequences of those disruptions because of their high 
prevalence of co-morbidities
36
 and fragmented care.
37
 As a combined consequence of their health 
and financial needs, dual eligibles make up a disproportionate share of both Medicaid and Medicare 
spending, and expenditures on dual eligibles are increasing. In 2003, there were four times more 
Medicare-only enrollees than dual eligible enrollees (30 million vs. 7 million), yet both groups had 
similar spending levels; $148 billion for Medicare-only enrollees and $138 for dual eligible enrollees.
38
 
In 2005, before Medicare Part D implementation, when Medicaid provided prescription drug coverage 
for dual eligibles, dual eligibles accounted for 46% of Medicaid spending ($132 billion), even though 
they represent only 18% of Medicaid enrollees.  
Dual eligibility and prior coverage 
By definition, dual eligibles experienced a different transition to Medicare Part D compared to 
enrollees covered only by Medicare. Before Medicare Part D, 20–30% of Medicare enrollees did not 
have prescription drug coverage.
39–41
 Dual eligibles receive coverage from Medicaid and Medicare, 
and, as a consequence, had prior coverage through Medicaid before Medicare Part D implementation. 
Prior coverage through Medicaid is significant because: 
 Even though Medicaid requires co-payments which can vary by state, all levels of Medicaid 
co-payments are lower than the minimum co-pay for Medicare Part D. 
8 
 Medicaid includes special protections that allow enrollees to obtain prescription drugs 
without co-pay if they are unable to afford the co-payment. 
 The majority of studies on Medicare Part D focus on populations without prior coverage, the 
sub-population that stood to benefit most from improved medication access.  
Medicare Part D  
Medicare Part D was designed to increase medication use and decrease out-of-pocket costs 
for prescription drugs. These benefits were largely realized, and Part D was associated with improved 
access to medication, demonstrated by increased medication use and lower cost for Medicare 
enrollees over the age of 65.
42–44
 Before Medicare Part D, Medicare did not include a pharmacy 
benefit. While many Medicare enrollees obtained supplemental coverage, 20-30% of Medicare 
enrollees did not have any prescription drug coverage before Medicare Part D was implemented.
39–41
 
Among the elderly (aged >65 years) without coverage, 50% spent $1,200 or more on prescription 
drugs in 2003.
45
 As the median income of individuals over the age of 65 was $16,000 and prescription 
drug spending presented a substantial cost burden (~8% of annual income).
46
 Of those who did not 
have prior coverage, 60–70% enrolled in a Medicare Part D plan 
47
 and, consequently, those without 
prior prescription drug coverage—i.e., those with the most unmet prescription needs—made up the 
majority of Medicare Part D enrollees. As a result, voluntary enrollment by Medicare enrollees without 
prior coverage may be a source of selection bias for studies of Medicare Part D implementation, 
where those that needed prescription drug coverage were more likely to enroll.  
Medicare Modernization Act 
The Medicare Modernization Act (MMA), the law that implemented Medicare Part D, was built 
on the assumption that competition among private plans would lower costs for enrollees and increase 
efficiency.
48
 Part D is available to beneficiaries only through private, stand-alone prescription drug 
plans. Unlike traditional Medicare, these prescription drug plans follow general CMS guidelines for 
Part D plans but have the flexibility to determine the details of the plan’s benefit (e.g., cost-sharing, 
utilization management).
49
 As part of its “non-interference” provision, the MMA also prohibits the 
federal government from negotiating with pharmaceutical companies for lower prices using the 
purchasing power of Medicare enrollees.
50
  
9 
Part D Prescription Drug Plans 
 Medicare Part D drug plans vary widely in how they structure their benefits, even within low-
income subsidy plans. There are several dimensions on which a benefit can vary, including 
deductibles, premiums, co-pays, and utilization management tools. The most common utilization 
management tools include prior authorization, step therapy, and quantity limits, all of which are used 
to control drug use and costs. Since implementation, Part D plans have been shown to vary 
significantly in the types of utilization management tools and the frequency with which they are 
applied.
49
 For a consumer to choose between prescription drug plans, they are required to weigh cost 
and benefit structures of prescription drug plans in combination with their anticipated health needs.  
Formulary Guidelines 
CMS designated six protected drug classes and required Part D formularies to cover “all or 
substantially all medications” within those drug classes. Drug classes were antidepressants, 
antipsychotics, anticonvulsants, anticancer drugs, immunosuppressants, and ART. However, despite 
the mandated inclusion of protected drug classes in all formularies, Part D plans were not required to 
cover all formulations of medications and were allowed to make use of utilization management within 
the six protected drug classes.
51
  
Low-Income Subsidy (LIS) Program 
OOP costs often present a barrier to medication access, so the MMA created the Low-
Income Subsidy (LIS) program to mitigate the effects of Medicare Part D’s mandated cost-sharing. 
The LIS, which is intended for low-income enrollees, reduces OOP costs associated with Part D by 
lowering or eliminating premiums, deductibles, copayments, coinsurance, and costs incurred during 
the coverage gap.
52
 All LIS plans that meet criteria set by Medicare and are referred to as 
“benchmark plans.” 
Dual eligibles receive the LIS automatically, because their enrollment in Medicaid is taken as 
qualification for LIS need.
52
 As such, their OOP costs are lower than the average Medicare Part D 
enrollee. Enrollment in LIS means that dual eligibles do not pay a monthly premium, have a $0 annual 
deductible, and are not subject to the Medicare Part D coverage gap (“donut hole”). Dual eligibles’ 
10 
cost-sharing through Medicare Part D is restricted to co-payments for prescription drugs because of 
their LIS auto-enrollment.  
Voluntary Enrollment for Non–Dual Eligibles 
Enrollment in Medicare Part D is voluntary for Medicare-only beneficiaries. For Medicare-only 
beneficiaries, the initial Medicare Part D enrollment period, which took place between November 15, 
2005, and May 15, 2006, was an opportunity to enroll in Part D plans where coverage would begin on 
January 1, 2006.
53
 Even though each subsequent annual open enrollment period provided Medicare-
only enrollees the opportunity to switch plans, only 13% elected to switch plans voluntarily between 
2006 and 2010, despite potential cost savings.
54
  
Auto-Assignment for Dual Eligibles 
There were several key differences between Medicare Part D enrollment for dual eligibles 
and Medicare-only enrollees. First, dual eligibles were auto-enrolled in Medicare Part D plans to 
minimize any disruptive effects of the transition. In other words, enrollment was involuntary. Dual 
eligibles were given a chance to select a prescription drug plan, much like Medicare-only enrollees, 
and if they did not select a plan, they were enrolled into a randomly selected benchmark plan. Second, 
all dual eligibles are enrolled in LIS prescription drug plans automatically, because they are already 
considered means-tested by Medicaid enrollment. Third, dual eligibles are able to switch plans at any 
point during the calendar year (i.e., there is no open enrollment period for this group).   
Random Reassignment for Dual Eligibles  
 When Part D plans lose benchmark status, CMS reassigns dual eligibles enrolled in the 
former benchmark plan to a new plan at the beginning of the calendar year. Dual eligibles who are 
reassigned receive a letter in October containing the name and contact information for their new plan. 
Since implementation, reassignment rates have been rising, because the number of available 
prescription drug plans has been shrinking. Between 2007 and 2010, the number of benchmark 
prescription drug plans dropped from 640 to 307. In 2010, approximately 15% of dual eligibles were 
reassigned because their 2009 plan lost its benchmark status in 2010.
35
 Although all plans must meet 
the same standards to be considered benchmark plans, there is formulary variation between plans. In 
2007, the gap in average formulary size (the number of prescription drugs available through 
11 
formularies) between the benchmark and non-benchmark formularies was 4%. By 2010, the gap in 
average formulary size had increased to 7% between plans, which differentially affect dual eligibles. 
Plan Selection 
Medicare Part D drug plan selection is based on the idea that individuals pick prescription 
drug plan with characteristics that will maximize their benefits while minimizing OOP costs. In theory, 
a larger number of Part D plans should allow individuals to tailor their plan selection more closely to 
their health needs, thereby maximizing benefits while minimizing OOP costs. However, Part D 
enrollees have indicated difficulties choosing plans that minimize their OOP costs. In 2006, only 12% 
of Part D beneficiaries chose the least expensive plan. Further, the same study went on to show that 
Part D beneficiaries could have reduced their prescription drug spending by 31% if they had selected 
a plan that was more closely aligned with their medication use.
55
 In addition to difficulties selecting 
plans at implementation, enrollees’ ability to select optimal plans given their health needs has not 
improved since implementation. In 2009, only 5% of beneficiaries chose the least expensive plan and 
overspent a median $331 on prescription drugs.
56
  
Despite sub-optimal plan selection over several years following Medicare Part D 
implementation, few enrollees switch plans. Among LIS beneficiaries, which all dual eligibles are, only 
11% switch in a given year, even though this population is not restricted to the annual enrollment 
window that voluntary Medicare enrollees adhere to and may switch plans every month.
40
 It is likely 
that few switch because of the complex plan characteristics and difficulties understanding the 
enrollment process.
57
  
Co-Functioning with ADAP  
 In addition to providing prescription drugs, ADAP can also be used to pay for premiums, co-
payments, and deductibles for individuals participating in ADAP. In recent years, ADAP has also been 
used to purchase health insurance and the proportion of ADAP enrollees served through insurance 
coordination is increasing, growing 14% from 2011 to 2012.
58
 Following Medicare Part D 
implementation, ADAP began picking up Medicare Part D cost-sharing expenses accrued by ADAP 
clients who were also Medicare enrollees. By May 15, 2006, ADAP was required to transition from 
paying for medication to paying for cost-sharing if the ADAP client was enrolled in Medicare Part D.
59
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In the specific case of dual eligibles with HIV, ADAP’s role is restricted to Part D copays because, by 
virtue of receiving LIS, dual eligibles do not pay Medicare Part D premiums and are not subject to the 
coverage gap.  
Medication Part D and OOP Costs 
The primary goal of Medicare Part D was to improve access to medication by lowering OOP 
costs. Previous research has shown a range of effect of Part D on OOP costs, where decreases in 
OOP costs range from 13% to 18%, or a reduction of $143 to $148 annually.
42,44,60–62
 These studies, 
however, do not take prior coverage into account. A 2010 study estimated the effects of OOP 
spending stratified by prior drug coverage (no coverage, Medicare HMO, Medigap, or employer-
sponsored coverage) and found lower odds of OOP spending in all groups except for the employer-
sponsored coverage.
63
 Dual eligibles transition from robust prior coverage through Medicaid to 
Medicare Part D, making them more analogous to having employer-sponsored coverage. In the 
single study in people with HIV on OOP spending following Medicare Part D implementation, 50% of 
Medicare Part D enrollees reported greater expenditures for prescription drugs under Medicare Part 
D.
64
  
Medicare Part D and Medication Use 
Cost-related nonadherence decreased from 14% to 12% between 2005 and 2006 in a 
representative sample of Medicare beneficiaries.
65
 However, analyses of vulnerable sub-groups, 
including the non-elderly (disabled and/or <65 years of age) Medicare enrollees, showed no 
significant changes in cost-related nonadherence after Part D.
66
 There was little change in a 2007 
follow-up study of disabled Medicare enrollees with 0–2 morbidities, and the unadjusted prevalence of 
cost-related non-adherence remained high in 2006, at 19% compared to the 12% in the elderly 
population of the same morbidity level. Similarly, the proportion of disabled Medicare enrollees 
foregoing basic needs to pay for medications ranged from 14% to 23% in 2006, compared to the 
elderly population, which ranged from 4% to -7%.
66
 Disabled Medicare enrollees who represent the 
majority of HIV-infected Medicare recipients, had high cost-related non-adherence and a substantial 
proportion were foregoing basic needs to pay for prescription drugs, even after Medicare Part D 
implementation.
66
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Medicare Part D and Dual Eligibles 
A systematic review of Medicare Part D implementation and its effects on medication use 
indicated that Medicare Part D was associated with increased medication use and decreased OOP 
costs in the general Medicare population, however its effects on dual eligibles and other vulnerable 
populations were mixed.
61
 This effect is underscored by survey findings from shortly after Medicare 
Part D implementation reporting that 20% of dual eligibles had experienced difficulties filing 
prescriptions after the transition to the new insurance program.
8
  
Medicare Part D and HIV  
 Prior to Medicare Part D implementation, policy analysts predicted that the transition would 
lead to ART interruptions both in the short-term due to the disruptive effect of the initial transition and 
in the long-term due to increased consumer cost-sharing.
34
 However, only two studies have examined 
the effects of Medicare Part D in people with HIV, and none examined clinical outcomes. A cross-
sectional study on people with HIV who received coverage through Medicare Part D showed an 
association between Medicare Part D implementation and self-reported ART interruption, where the 
odds of ART interruption were six times higher among those covered by Medicare Part D. This study 
also reported that increased cost was the primary barrier associated with ART interruption.
9
 However, 
the sample size in this study was small; out of 125 homeless and marginally housed individuals, 
results are based on 10 patients who reported Medicare Part D coverage. Self-reported difficulties 
accessing medication in people with HIV were echoed in a second study, where reports by HIV 
providers indicated that the majority of their patients experienced difficulties accessing their 
prescription drugs under Medicare Part D.
10
 
Medicare Part D and Psychotropic Medication Use 
Psychotropic drugs may be particularly affected by Medicare Part D for several reasons. First, 
although CMS protections apply to psychotropic drugs, requiring all plans to cover “most or all” drugs 
within that drug class, a study by Huskamp et al. indicated that even though prescription drugs within 
protected drug classes are generally covered, many product formulations of those prescription drugs 
are often not covered by the low-income plans that dual eligibles are enrolled into.
51
 Second, 
utilization management requirements for psychotropic drugs have increased since 2006, posing 
14 
potential access barriers specific to psychotropic drugs.
67
 In addition to studies documenting 
formulary restrictions for psychotropic medication, a study of dual eligible psychiatric patients 
revealed that 27.6% had to switch medications due to formulary restrictions in the first year following 
the transition from Medicaid to Medicare Part D.
68
 In a study restricted to dual eligible beneficiaries 
with mental illness, 44% of patients experienced problems accessing medication. As a result of drugs 
not being covered or approved, 19% switched to different medications and 22% indicated that they 
had difficulty accessing medication because of copayments.
69
  
Literature Gap  
 Despite research suggesting that Medicare Part D affects dual eligibles differently than 
Medicare-only enrollees, there is limited evidence on the effects of Medicare Part D on dual eligibles 
with HIV. In the two studies on Medicare Part D and people with HIV, even though the majority of 
individuals studied were likely to have been dual eligible, the studies focused on people with HIV who 
are enrolled in Medicare, which included both dual eligibles and Medicare-only enrollees. Further, 
there are no studies that examine the effect of Medicare Part D on clinical outcomes in either 
Medicare-only enrollees with HIV or in dual eligibles with HIV.  
 This study is the first to estimate the effects of Medicare Part D on OOP costs, use of ADAP, 
and depression- and HIV-related outcomes in dual eligibles with HIV. We used six years of data from 
a long-term prospective cohort study—the Women’s Interagency HIV Study (WIHS), which is 
designed to study the natural and treated course of HIV infection in women. Advantages of these data 
include a dual eligible population observed at interval-based study visits, data that are independent of 
pharmacy use or care engagement, a control group for temporal trends, and availability laboratory 
measures of HIV VL. 
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Figure 1. Conceptual model. 
 
Conceptual Model 
The conceptual model (Figure 1) of this study hinges on two components: 1) the direct, 
immediate, and continuous effect of Medicare Part D on medication use and 2) dual eligibles’ 
vulnerability to medication disruptions or changes (Figure 2). Dual eligibles lost their Medicaid 
prescription drug coverage benefits as a result of Medicare Part D implementation and were enrolled, 
often at random, into Medicare Part D prescription drug plans. The transition from Medicaid’s 
prescription drug benefit to Medicare Part D exposed dual eligibles to variability in formularies, cost-
sharing, and utilization management tools.  
Once dual eligibles transitioned to Medicare Part D, annual benchmark plan requirements 
exposed them to plan instability because many prescription drug plans did not meet the benchmark 
requirements from year to year. Dual eligibles enrolled in benchmark plans that do not meet the 
Medicare Part D requirements the following year are then randomly re-assigned to new plans that do 
meet benchmark standards. As a consequence, dual eligibles can be auto-enrolled into plans with 
different formularies and restrictions each year. In addition to the potential effects of formulary 
variation and plan instability, characteristics of dual eligibles with HIV, such as having multiple co-
16 
morbid conditions and reduced ability to pay for prescription drugs, have the potential to exacerbate 
the effects of Medicare Part D.  
 
 
Figure 2. Characteristics of Medicare Part D and dual eligibility. 
 
The goal of Medicare Part D was to improve access to medication for Medicare enrollees by 
reducing costs. Medicare Part D had beneficial effects for Medicare enrollees, improving medication 
use and reducing OOP costs. However, prior research indicates that vulnerable subgroups of 
Medicare enrollees, including dual eligibles, experienced fewer of Medicare Part D’s benefits and, in 
some studies, dual eligibles reported difficulties accessing medications due to increased costs and 
restrictive formularies or access rules. Although cost-sharing is low under Medicare Part D, even 
small increases in cost-sharing have been shown to shift medication use, and the extremely low 
income of the WIHS population of HIV-infected dual eligibles may make them more vulnerable to 
even small increases in OOP costs.  
In addition to its potential effects on medication use, increased cost-sharing may result in a 
greater proportion of dual eligibles using ADAP to reduce OOP costs. People with HIV use ADAP to 
access ART but can also use the program to access medication for common comorbidities. Even 
though all ADAP cover ART, ADAPs are not required to cover psychiatric medication such as 
antidepressants. However, states with WIHS sites of this study (CA, DC, IL, NY) all included 
antidepressants in their ADAP formularies during the years in this study (2003–2008). Consequently, 
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ADAP use may have mitigated effects of Medicare Part D on both ART adherence and 
antidepressant use in this population. The relationship between ART and viral suppression is well-
established, as is the relationship between antidepressant use and depressive symptoms. And finally, 
both depressive symptoms and unsuppressed HIV VLs have been associated with hospitalization.  
Contribution of this Study 
This study is the first to quantify the effects of Medicare Part D implementation on dual 
eligibles with HIV, an understudied and costly population whose medical and financial vulnerabilities 
and potential for shifting HIV transmission have made them a national priority through the Affordable 
Care Act (ACA). Examining dual eligibles with HIV has significance because their low income, co-
morbidities,
36
 and fragmented care
37
 make this population uniquely vulnerable to medication 
disruptions. Consequently, even though dual eligibles with HIV represent a small proportion of total 
enrollment in Medicare Part D, they remain a subgroup with strong policy implications.
70
 
Prescription drug plan instability and variation are potentially significant drivers of Medicare 
Part D’s effects. Dual eligibles face Medicare Part D plan instability because available plans change 
annually
35
 and can result in random re-assignment if the originally assigned plan is no longer 
available. The interest in strategies to mitigate coverage volatility is driven by CMS and underscored 
by the ACA.
71
 Research on the effects of Medicare Part D implementation over time can provide 
evidence that shapes those strategies.  
Possible ART disruption associated with Medicare Part D has the potential to affect the HIV-
negative population, in addition to its direct effects on medication access for dual eligibles with HIV. 
Estimating the effects of Medicare Part D implementation on outcomes in people with HIV has 
significance for reducing HIV transmission on a population level. Consistent treatment for both HIV 
and depressive symptoms have strong implications for reducing HIV transmission at the population 
level and are the cornerstone of the test-and-treat model.
18
  
Policy Implications 
 For the majority of people with HIV, Medicaid and Medicare coverage are essential for 
consistent medication access. Changes in benefits, such as the transition from Medicaid’s 
prescription drug coverage to Medicare Part D, have the potential to affect medication access and 
18 
out-of-pocket costs, and, consequently, medication adherence, health outcomes, and service use. 
Optimal ART use has been associated with less virologic failure, fewer hospitalizations, and life 
expectancies that are comparable to those of HIV-negative individuals. In addition to individual-level 
impact, early and consistent ART reduces HIV transmission to uninfected partners through sexual 
behavior or drug use, resulting in lower HIV incidence.  
In addition to medication use and health outcomes, this study also examines the effect of 
Medicare Part D on OOP prescription drug spending and ADAP use. In 2012, the national ADAP 
budget grew to $2.03 billion annually,
58
 up 8% from the previous year. Because Medicare Part D and 
ADAP are both designed to improve access to prescription drugs, understanding whether and how 
Medicare Part D affects ADAP use can contribute to strategies for maximizing the cost-effectiveness 
of both programs.  
Finally, consistent medication access for dual eligibles requires the successful coordination of 
both coverage sources, Medicare and Medicaid. The ACA prioritizes improved care coordination for 
dual eligibles in general
74
 and for dual eligibles with HIV in particular. The ACA emphasizes care 
coordination for dual eligibles through ACA provisions and has created the Federal Coordinated 
Health Care Office, which is dedicated to translating research on dual eligibles into evidence-based 
policy.
75
 This study provides estimates of how dual eligibles responded to the initial transition to 
Medicare Part D in 2006, which represents a similar transition to the one that people with HIV 
undergo when they enroll in Medicare Part D currently. This study also provides estimates of 
medication use, health outcomes, and service use for this vulnerable and costly population in the time 
period after Medicare Part D implementation in 2006 leading up to ACA implementation in 2014.  
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CHAPTER 3: METHODS 
This study examined the effects of Medicare Part D implementation on OOP prescription drug 
spending, health outcomes, medication use, and hospitalization among dual eligibles with HIV. The 
proposed study used data from semiannual WIHS visits between 2003 and 2008. All outcomes of 
interest were examined by comparing the time periods before and after the transition to Medicare Part 
D. Dual eligibles' automatic and immediate exposure to Medicare Part D after auto-enrollment on 
January 1, 2006, was a natural experiment and made this a quasi-experimental study. A difference-
in-differences approach (DiD) was used to estimate the average effect of Medicare Part D in dual 
eligibles with HIV while accounting for temporal trends using a matched control group of Medicaid-
only enrollees.     
To estimate a valid average effect, the DiD approach must satisfy the common trend 
assumption, meaning that the comparison group must follow a parallel pre-treatment trend as dual 
eligibles, the analytic group of interest. Our analyses expanded on conventional DiD analysis by 
matching dual eligibles with a Medicaid-only comparison group using a propensity score matching 
approach. Under the assumption that the matching captures all relevant differences between the two 
groups, this matched control group represented the counterfactual outcomes of dual eligibles, i.e., 
dual eligibles had they not transitioned to Medicare Part D. 
Quasi-Experimental Study Design 
A quasi-experimental study is defined as a study where treatment randomization is 
impossible or unfeasible, yet retains similarities with a randomized experiment.
76
 This study mimics a 
randomized experiment in that temporal order is clearly established and, within dual eligibles, 
individual characteristics are unlikely to affect the exposure to Medicare Part D. Within quasi-
experimental studies, causality is strengthened when alternative causal explanations for the 
estimated association are implausible. In randomized experiments, alternative causal explanations 
are made implausible by treatment randomization and the consequent balanced distribution of 
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covariates. In quasi-experimental studies, alternative causal explanations must be ruled out by 
minimizing 1) confounding and 2) threats to validity. 
 
 
Figure 3. Directed acyclic graph of exogeneity of Medicare Part D implementation (Z) and the effect 
on medication use (T) and outcome (Y). 
 
Figure 3 illustrates a common limitation of studies on insurance coverage. The estimation of 
the causal effect of prescription drug coverage (T) on an outcome (Y) requires adequate 
measurement and control of confounding by individual characteristics (U). Because those 
confounding factors are often unobserved, adequate statistical control can be difficult and analyses 
can result in biased estimates (Figure 3a). By contrast, the use of an exogenous policy 
implementation (Z), such as Medicare Part D implementation, that determines prescription drug 
coverage (T) but is unaffected by individual characteristics (U) and has no direct effect on the 
outcomes of interest (Y) limits alternative causal explanations for an observed effect (Figure 3b).
76
  
Individual characteristics of dual eligibles are unlikely to influence prescription drug coverage 
because dual eligibles are auto-enrolled in Medicare Part D. Auto-enrollment strengthens the 
assumption that the exposure to Medicare Part D is exogenous (Figure 3) and limits the potential for 
common-cause confounding of Medicare Part D implementation and the outcomes of interest. The 
primary threat to validity is the possibility of an event unrelated to Medicare Part D temporally 
coinciding with Medicare Part D implementation and affecting outcomes of dual eligibles. If that were 
the case, any effect detected within dual eligibles could be misattributed to Medicare Part D despite 
21 
being caused by an unrelated event. The DiD approach attempts to adjust for temporal trends by 
inclusion of a control group, detailed in the section on propensity score matching. 
Data Source and Study Population 
 The primary goal of the proposed study is to estimate the effects of Medicare Part D 
implementation on Medicaid-Medicare dual eligibles in the WIHS. The WIHS is an ongoing 
observational study that recruited HIV-positive and HIV-negative women from six original sites in the 
United States: Washington, DC; the Bronx, NY; Chicago, IL; Los Angeles, CA; and San Francisco, 
CA. Since enrollment began in 1994, WIHS data have been used to study HIV disease progression. 
Study visits are conducted every six months and collect data from scripted interviews (self-reported) 
as well as clinical examination, laboratory measurements, and surveillance (e.g., cancer registries, 
National Death Registry). At each WIHS visit, the WIHS collects information on medical history, ART 
and other prescription medications, drug use, sexual behavior, health care use, and depressive 
symptoms. 
 The WIHS has enrolled participants in four waves: 1994-1995, 2001-2002, 2011-2012, and 
2013-2014. A comparison of the first two enrollment waves showed that participants did not differ by 
ethnicity, income, or education. Changes in recruitment strategy resulted in differences by age and 
HIV disease stage between participants enrolled in the 1994-1995 and the 2001-2002 enrollment 
waves, where participants recruited in 2001-2002 had less advanced HIV disease and were younger 
than the women recruited in 1994-1995. Only participants enrolled in the first two waves (1994-1995, 
2001-2002) were used in the proposed study because only those participants could have been 
transitioned to Medicare Part D in 2006. This study included available measures from all semi-annual 
WIHS visits between 2003 and 2008. 
Inclusion and Exclusion Criteria 
Of the 3,398 HIV-infected women who were enrolled in the WIHS by fall 2014, we restricted 
the time frame of our analysis to 2003–2008 and excluded women who had missed three consecutive 
visits between 2003 and 2008. Of the 1,807 women remaining, we further restricted the study to 
participants who were dual eligible or Medicaid-only in 2005 (n=801), before Medicare Part D 
implementation.  
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Measures 
Data Collection 
All WIHS participants complete a structured, in-person interview every six months, either in 
English or in Spanish. At each study visit, interview data collected include sociodemographic 
characteristics, medical and health history, obstetric and gynecologic history, sexual and drug use 
behaviors, use of healthcare services, and psychological factors. All study visits also include a 
physical and gynecologic examination, medical record abstraction, and collection of laboratory 
specimens. For HIV-infected women, laboratory specimen collection includes quantification of HIV VL 
levels and CD4 cell count.  
Exposure Definition and Assessment 
 This study’s exposure of interest was the transition from Medicaid’s prescription drug 
coverage to Medicare Part D. Time period was used to assign dual eligibles’ exposure to the 
Medicare Part D transition. A binary variable was created to indicate the pre– and post–Medicare Part 
D time periods (2003–2005 and 2006–2008, respectively). For dual eligibles, 2003–2005 represents 
prescription drug coverage under Medicaid and 2006–2008 represents prescription drug coverage 
under Medicare Part D. Dual eligibles are considered unexposed in the pre–Medicare Part D time 
period and exposed during the post–Medicare Part D time period. The Medicaid-only comparison 
group was considered unexposed for both time periods because these women only received 
prescription drug coverage through Medicaid during both time periods (Error! Reference source not 
ound.). 
 
Figure 4. Dual eligibles and comparison group insurance coverage over time. 
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Outcome Overview 
For these analyses, we estimated the effects of Medicare Part D implementation on two broad 
outcome categories: 1) HIV-related and 2) depression-related (Table 1). Within HIV-related outcomes 
(Aim 1), we estimated changes in OOP prescription drug spending, ADAP use, ART adherence, and 
viral suppression. In Aim 2, we estimated depression-related outcomes, including antidepressant use, 
depressive symptoms, and hospitalization. Details on outcome coding and effects estimated are 
included in Table 1. 
 
Table 1. Outcome Definitions and Effect Estimates, by Aim 
Aim Outcome  Type Estimated Treatment 
Effect 
Coding 
A
im
1
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OOP prescription 
drug spending 
Binary Difference in proportion 
with any OOP spending 
on prescription drugs 
Since last visit: 
1: Any OOP spending 
0: No OOP spending  
ART adherence* Binary Difference in proportion w/ 
100% ART adherence 
Since last visit: 
1: <100% adherent 
0: 100% adherent 
ADAP use Binary Difference in proportion 
using ADAP  
Since last visit: 
1: ADAP use 
0: No ADAP use  
Viral suppression Binary  Difference in proportion 
who were virally 
suppressed  
At current visit:  
1: VL ≥200 copies/mL 
0: VL <200 copies/mL 
A
im
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: 
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Antidepressant use Binary Difference in proportion 
using antidepressants 
At current visit: 
1: any antidepressant use  
0: no antidepressant use 
Depressive 
symptoms 
Binary Difference in proportion 
with severe depressive 
symptoms  
At current visit: 
1: CES-D score ≥16 
0: CES-D score <16 
Hospitalization Binary Difference in proportion 
hospitalized 
Since last visit: 
1: any hospitalization 
0: no hospitalization 
* restricted to the subset of participants who were on ART 
 
 
 
Statistical Power 
Power analyses were conducted to determine the minimum detectable difference in 
proportion for the primary outcomes of both aims, given the available sample size of dual eligibles in 
the WIHS and an 80% power threshold. To demonstrate adequate power for the pre-post comparison 
of the primary outcome for Aim 1, ART adherence, the calculation assume a pooled standard 
deviation of 25–29%.
77
 For a pre-post comparison of mean adherence in dual eligibles, our power 
analyses indicated that a simpler, pre-post comparison showed 80% power to detect a 5% change in 
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mean adherence. Similarly, we estimated that Aim 2 was powered at 80% to detect a 10% change in 
the proportion of dual eligibles who had an undetectable VL. For both aims, power was calculated 
specifying a two-sided Type I error probability (α) of 0.05 and included a design effect to the 
reweighted number of dual eligibles to account for clustering. The design effect was calculated using 
the number of dual eligibles in the analytic sample.  
Statistical Analyses 
Visualizing non-parametric trends (Lowess plots) 
Before propensity score matching, we plotted outcome variables for visits from 2003 to 2008 
using a segmented locally weighted smoothed spline (Lowess)
78
 to visualize trends for dual eligibles 
and Medicaid-only participants. The plots were segmented at Medicare Part D implementation on 
January 1, 2006, to visualize any discontinuities associated with the transition. Non-parametric 
methods have the advantage that they do not require assumptions about the relationship between 
variables.  
Propensity score matching  
Observational studies often examine relationships between exposure and outcome that are 
both associated with or confounded by participant characteristics. Propensity scores are a tool to 
balance groups on measured covariates and improve the validity of the control group as a 
counterfactual for the analytic group of interest. In this study, we estimated the effect of Medicare Part 
D in the dual eligibles rather than the average effect in the full study sample. Consequently, we 
matched the two groups to set the distribution of covariates in the Medicaid-only participants equal to 
the distribution in the dual eligibles. This matching approach sets the Medicaid-only enrollees to 
represent the dual eligibles by aligning the pre–Medicare Part D characteristics of the Medicaid-only 
group with those of the dual eligibles.  
In creating the propensity score, we evaluated covariates by considering the effect that their 
inclusion had on standardized differences between the two groups following the match. To exclude 
covariates that could have been affected by Medicare Part D implementation, we restricted our set of 
covariates to pre–Medicare Part D values. A second consideration was the number of covariates that 
could be included in a propensity score model. Because the number of dual eligibles in our sample 
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was small, we were unable to include all possible covariates and were limited to a set of 10 to 15. We 
created separate sets of propensity scores for the two aims because we were trying to balance the 
two groups on slightly different characteristics. 
After calculating a propensity score for each observation, we conducted balance diagnostics 
to evaluate whether the propensity score model had been adequately specified. We confirmed that 
the range of propensity scores between dual eligibles and Medicaid-only enrollees had sufficient 
overlap (“common support”). Propensity scores must overlap sufficiently between groups because no 
causal contrast can be made for individuals who do not have a counterfactual within the other group. 
Common support was assessed by examining the distribution of propensity scores by group for both 
aims.  
We also examined the standardized differences in covariates before and after matching. 
Standardized differences represent a comparison of the covariate means in units of the pooled 
standard deviation. Standardized differences provide a way to compare the matched and unmatched 
means of baseline covariates between dual eligibles and Medicaid-only participants. In addition to 
standardized differences, we also compared the distributions of baseline covariates within strata of 
propensity scores. If propensity score models are specified correctly, baseline covariates should be 
evenly distributed within strata of propensity scores.  
After confirming adequate balance, we used the propensity scores to match dual eligibles to 
Medicaid-only participants, using a 1:1 matching without replacement. In matching without 
replacement, after a Medicaid-only participant was matched to a dual eligible, that Medicaid-only 
participant was no longer available to be matched to another dual eligible. Each dual eligible whose 
propensity score was within the range of common support was matched with a Medicaid-only 
participant, such that the matched pair had similar propensity score values. Pairs were matched to 
minimize the within-pair difference in propensity scores. After creating the matched sample, the 
effects of Medicare Part D on outcomes could be estimated by comparing the two groups.  
Difference-in-Differences 
The principle behind DiD can be represented in a 2x2 table (Table 2, adapted from Stuart et 
al.
79
), where the DiD estimate is the change in average outcome ?̅? over time and between groups (Δ). 
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Intuitively, the change over time in the dual eligibles (?̅?1,𝑝𝑜𝑠𝑡 −  ?̅?1,𝑝𝑟𝑒) can be thought of as a 
combination of the change in ?̅? due to Medicare Part D implementation, the exposure of interest, and 
also any secular time trends, which we would like to remove. The change over time in the Medicaid-
only comparison group represents those secular trends and by removing that group’s change over 
time, we are able to isolate the effects of Medicare Part D on outcomes in dual eligibles.  
 
Table 2 Difference-in-Differences Design 
 Dual eligibles Medicaid-only 
(comparison group) 
Difference 
(between groups) 
Pre-Part D  ?̅?1,𝑝𝑟𝑒  ?̅?0,𝑝𝑟𝑒 ?̅?1,𝑝𝑟𝑒 − ?̅?1,𝑝𝑟𝑒 
Post-Part D ?̅?1,𝑝𝑜𝑠𝑡 ?̅?0,𝑝𝑜𝑠𝑡 ?̅?1,𝑝𝑟𝑒 − ?̅?1,𝑝𝑟𝑒 
Change  
(over time) 
?̅?1,𝑝𝑜𝑠𝑡 −  ?̅?1,𝑝𝑟𝑒 ?̅?0,𝑝𝑜𝑠𝑡 − ?̅?0,𝑝𝑟𝑒 Δ = (?̅?1,𝑝𝑜𝑠𝑡 − ?̅?1,𝑝𝑟𝑒) − ( ?̅?0,𝑝𝑜𝑠𝑡 −  ?̅?0,𝑝𝑟𝑒) 
  = (?̅?1,𝑝𝑟𝑒 − ?̅?0,𝑝𝑟𝑒) − ( ?̅?1,𝑝𝑜𝑠𝑡 − ?̅?0,𝑝𝑜𝑠𝑡) 
 
 
A key assumption of the DiD approach is that the Medicaid-only group is a valid 
counterfactual representation of the trends over time that the dual eligible group would have 
experienced had they not been exposed to Medicare Part D. This assumption is made more 
reasonable through two study design choices in this study: selection of the comparison group and 
propensity score matching. Selection of the comparison group can be advantageous to the study’s 
validity if the comparison group captures unobserved trends that cannot be adjusted for using a 
propensity score based on measured covariates. We selected the Medicaid-only participants as the 
comparison group, as opposed to the privately insured or the uninsured, because dual eligibles and 
Medicaid-only participants have the same prescription drug coverage through Medicaid in the pre–
Medicare Part D time period. By holding baseline prescription drug coverage constant, this 
comparison group is likely to reflect a range of unobserved trends in medication access, cost-sharing, 
enrollment criteria, and utilization management tools associated with Medicaid’s prescription drug 
coverage. Our intentional choice of comparison group strengthens the assumption that the two 
groups have similar access to prescription drugs before Medicare Part D implementation and that 
their trends in medication use were similar. Second, we estimated propensity scores to match the two 
groups on measured covariates, and were able to ensure that we only included participants who were 
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within the common range of propensity scores between the two groups (common support). By 
restricting the DiD analysis to individuals who were within the overlapping range of propensity scores, 
we strengthen the exchangeability assumption. Finally, it is worth noting that the characteristics of the 
DiD design mean that the outcome levels may differ between groups in the pre–Medicare Part D time 
period but that the validity of the approach depends on outcome trends in the pre–Medicare Part D 
time period being similar.
79
  In our study, we conducted a propensity score matched DiD model using 
the matched cohort of a 1:1 nearest neighbor matched cohort of dual eligibles and Medicaid-only 
participants (matched DiD model). The results for the propensity score matched DiD model are 
presented in Chapters 4 and 5, by aim.  
 In this study, the effect of Medicare Part D was estimated on a range of outcomes using a 
DiD approach in a matched sample. For binary outcomes, the effect we estimated was the difference 
between proportion of participants experiencing the outcome in the dual eligible group and proportion 
of participants experiencing the outcome in the Medicaid-only group. For continuous outcomes, the 
effect we estimated was the difference in mean outcome of dual eligibles and the mean outcome of 
Medicaid-only participants. We fit a linear regression model to our longitudinal data, where each 
observation represented a person-visit. Linear regressions were used to model each outcome as a 
function of group, time period, and an interaction term for time period (pre- vs. post-Medicare Part D) 
and insurance group (dual eligible vs. Medicaid-only).    
Sensitivity Analyses 
Insurance coverage switching ("churning")  
Insurance coverage can change over time due to temporary changes in eligibility. We 
explored the effects of transitioning on and off of insurance coverage (“churning)” in both dual 
eligibles and Medicaid-only participants and its effects on study results in these sensitivity analyses. 
Despite an annual reapplication process, previous studies have shown that dual eligibles rarely 
transition in and out of Medicaid.
80
 In a study of non-elderly dual eligibles, it was estimated that 85% 
of participants received continuous coverage through Medicaid in 2004 and 2005.
81
 It is similarly 
unlikely that Medicare coverage would be lost once disability has been established; the majority of 
people with HIV become eligible for Medicare by meeting disability criteria and dual eligibles can 
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therefore be expected to retain their Medicare coverage throughout the study period. Churning is a 
more common problem for Medicaid enrollees. A study on the loss of Medicaid coverage indicated 
that within adults, 20%, 43%, and 55% disenrolled from Medicaid within 6, 12, and 23 months after 
initial Medicaid enrollment, respectively. Six months following disenrollment, 17% of adults had re-
enrolled in Medicaid. However, Medicaid eligibility depends on both financial criteria and categorical 
eligibility (i.e., disability, welfare, pregnancy) and individuals who are eligible for Medicaid based on 
disability criteria are more stable in their Medicaid coverage, where 30% of Medicaid enrollees lost 
coverage within 12 months.
82
 Based on previous studies, we estimated that approximately 85% of 
dual eligibles maintained continuous Medicaid coverage over the course of a year of Medicaid 
enrollment, and approximately 70% of Medicaid-only enrollees maintained their Medicaid coverage. 
To assess the sensitivity our analyses to insurance coverage loss, we explore the proportion of time 
that the dual eligible group and the Medicaid-only group spent as their reported insurance type in 
2005 to demonstrate their having spent the majority of their time-on-study as either dual eligible or 
Medicaid-only in both pre– and post–Medicare Part D time periods.  
ART adherence threshold  
Initially, we examined adherence using a threshold of 100% ART vs. <100% ART adherence. 
Alternate categorization of ART adherence were based on previous research, which indicated that 
≥95% adherence was necessary to achieve viral loads at <400 copies/mL 80% of the time.
83
 By 
definition, analyses of ART adherence were also restricted to the subset of the analytic sample that 
was on ART.  
Comparison group validity  
For the Medicaid-only beneficiaries to be a valid comparison group for dual eligibles, the two 
groups must have sufficiently overlapping outcome distributions prior to Medicare Part D 
implementation. The balance diagnostics for the propensity score strengthen the validity assumption. 
Based on a priori knowledge about differing health and demographic profiles, we assumed—
correctly—that the unmatched sample would differ on mean, pre–Medicare Part D outcome values 
between the groups. However, DiD still represents a valid analysis in the case where outcome levels 
differ at baseline, as long as the observed trends between the groups are parallel, which they were 
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for all outcomes. However, in the case of ADAP use, there was mixed evidence that people with HIV 
who were enrolled in Medicaid-only were able to access ADAP—its intended purpose is to provide 
medications to those with inadequate coverage. To test the sensitivity of our ADAP result to the 
comparison group, we ran additional DiD analyses using other insurance types as comparison groups 
(privately-insured, uninsured).  
Long-term vs. short-term effects 
 We calculated changes in outcomes for the primary time frame of interest (2003-2008), 
averaging outcomes over three years pre- and post-Medicare Part D implementation. In addition, we 
calculated changes in outcomes using two abbreviated time frames: 2004-2007 and 2005-2006.  
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CHAPTER 4: EFFECTS OF MEDICARE PART D ON MEDICATION ACCESS, ADHERENCE, AND 
VIRAL SUPPRESSION (AIM 1) 
The objective of Aim 1 was to estimate the effect of Medicare Part D on self-reported OOP 
prescription drug spending, ADAP use, ART adherence, and HIV VL suppression among dual 
eligibles with HIV. We hypothesized that we would observe an increase in OOP prescription drug 
spending and in ADAP use. We further hypothesized that the increase in OOP prescription drug 
spending would lead to increased ART nonadherence and that this treatment disruption would reduce 
viral suppression.  
Introduction 
More than half of U.S. adults with HIV (56%) receive health insurance coverage through 
Medicare or Medicaid.
84
 Medicare is a federally administered program that provides health insurance 
to Americans age 65 and over as well as persons with permanent disabilities under age 65 who 
receive Social Security Disability Insurance.
4
 Medicaid programs are state-run and have traditionally 
provided health insurance to certain categories of low-income persons.
85
 Ten percent of adults with 
HIV meet eligibility criteria for both Medicare, primarily through disability criteria rather than age, and 
Medicaid, through a combination of income and disability criteria, and are enrolled in both programs 
(“dual eligibles”).
86
 For dual eligibles, Medicare provides primary coverage while Medicaid absorbs 
remaining costs and covers services not available through Medicare.
85
 In addition to Medicaid and 
Medicare, AIDS Drug Assistance Programs (ADAP) serve as a safety-net program, providing HIV-
related prescription drugs to low-income individuals who have limited prescription drug coverage.
59
 
Dual eligibles with HIV rely on these programs for consistent access to ART, which is crucial to 
maintaining HIV viral load (VL) suppression.
87
  
For adults enrolled in Medicaid, most states offer a prescription drug benefit with a broad 
formulary with little to no cost-sharing, including protections that allow enrollees to receive their 
prescriptions without a co-payment, based on ability to pay.
34
 Prior to the implementation of Medicare 
Part D in January 2006, Medicare coverage did not include an outpatient prescription drug benefit 
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and dual eligibles received prescription drug coverage through Medicaid. Since then, coverage for 
prescription drugs has shifted from Medicaid to Medicare and dual eligibles were required to enroll (or 
be auto-enrolled) in Medicare Part D for prescription drug coverage at implementation.
88
  
Medicare Part D is administered by private prescription drug plans that mandate cost-sharing 
and vary in the lists of covered drugs (formularies) and rules for accessing those drugs (utilization 
management).
34,89
 Prior to implementation, policy analysts anticipated that the initial transition would 
disrupt ART use for people with HIV in the short-term due to changes in which drugs are covered and 
in the long-term due to increased consumer cost-sharing as their prior coverage through Medicaid 
was replaced by Medicare Part D.
34
 Among people with HIV, disruptions in ART can lead to 
decreased ART adherence and VL suppression, which promote HIV-related morbidity and mortality.
11
 
For example, a survey conducted shortly after Medicare Part D implementation reported that 
20% of dual eligibles experienced difficulties filling prescriptions after the transition to Medicare Part 
D.
8
 Difficulties filling prescriptions included paying more out-of-pocket for prescription drugs than 
under Medicaid, needing drugs not covered on their plan’s formulary, and delayed auto-enrollment 
into Medicare Part D drug plans.
8
  
Only two cross-sectional studies have examined the effects of Medicare Part D on people 
with HIV, shortly after implementation. One study found that the odds of ART interruption were six 
times higher among those covered by Medicare Part D compared to those with other or no 
insurance.
9
 Increased cost was the primary barrier associated with ART interruption. These findings -
are supported by reports from HIV providers that the majority of patients had difficulties accessing 
their prescription drugs under Medicare Part D.
10
 Despite reported ART interruption, no studies have 
examined the effects of Medicare Part D on HIV clinical outcomes, such as HIV VL suppression. Self-
reported out-of-pocket spending on prescription drugs was of interest because reports of dual 
eligibles with HIV linked increases in out-of-pocket cost to ART interruption after Medicare Part D,
9
 
even though research on the elderly Medicare population indicated improved medication access after 
Medicare Part D.
90
 Further, no studies have examined effects of Medicare Part D implementation on 
ADAP use, despite reported coordination between Medicare Part D and ADAP.
91
 The effects on 
ADAP are of interest because, in addition to providing prescription drugs, ADAP can also provide 
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wrap-around coverage for people who have certain types of prescription drug coverage but who still 
face financial barriers to accessing their medications, such as individuals under Medicare Part D.
27
  
 This study is the first to estimate the effects of Medicare Part D on out-of-pocket prescription 
drug spending, ADAP use, ART adherence, and viral suppression in dual eligibles with HIV. We used 
six years of data from the Women’s Interagency HIV Study (WIHS), designed to comprehensively 
investigate the effects of HIV infection and treatment in women. The WIHS data include laboratory 
measures of HIV VL and are independent of insurance or pharmacy use, a distinct advantage over 
clinic or pharmacy claims data. 
Methods 
Data Source 
 The WIHS is the largest multisite prospective cohort study of HIV-infected and uninfected 
women in the United States.
92,93
 During the time frame for this analysis (2003–2008), the six original 
WIHS study sites were located in the Bronx, NY; Brooklyn, NY; Washington, DC; San Francisco, CA; 
Los Angeles, CA; and Chicago, IL. Since enrollment began in 1994, the WIHS has collected data on 
3,679 HIV-infected participants. Biannual study visits include a physical examination, clinical 
laboratory measurements, and behavioral questionnaires.  
Design and Study Sample 
We estimated changes in out-of-pocket prescription drug spending, ADAP use, ART 
adherence, and viral suppression of dual eligibles after Medicare Part D implementation compared to 
a matched sample of Medicaid-only enrollees. We excluded women who missed three consecutive 
visits between 2003 and 2008. We restricted the analysis to participants who 1) were HIV-infected by 
January 1, 2003, 2) had at least one study visit in both 2005 and 2006, and 3) reported Medicaid-
Medicare dual eligibility or Medicaid-only enrollment at Medicare Part D implementation on January 1, 
2006. Among 1,634 HIV-infected participants, 1,449 (87%) women had least one visit in 2005 and 
one visit in 2006. Of those, 801 women met the insurance coverage inclusion criteria for this study, of 
whom 125 were dual eligibles and 676 had Medicaid only. This study did not include HIV-uninfected 
WIHS participants or participants who received primary coverage through sources other than 
Medicaid and Medicare. All participants were under the age of 65 at Medicare Part D implementation 
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and were assumed to have gained Medicare coverage through disability criteria, rather than age.  
Measures  
Health Insurance Status  
The exposure of interest was the transition to Medicare Part D. Participants reporting dual 
eligibility in 2005 were considered dual eligible at Medicare Part D implementation on January 1, 
2006. The control group included participants reporting Medicaid coverage and no other private or 
public insurance in 2005 who were considered Medicaid-only at Medicare Part D implementation. We 
selected Medicaid-only participants because the two groups had identical prescription drug coverage 
through Medicaid in the pre–Medicare Part D time period.  
Outcomes of Interest 
Several outcomes were considered: 1) self-reported out-of-pocket spending on prescription 
drugs, 2) self-reported ADAP use, 3) self-reported ART adherence, and 4) HIV viral suppression.  
Out-of-pocket spending on prescription drugs was categorized as “none”, “<$25”, “$25–$200”, 
“$201–$500”, and “>$500.” Participants reported out-of-pocket prescription drug spending since the 
last study visit (the past six months). Spending was collapsed to create a binary indicator for any out-
of-pocket prescription drug spending versus none because only 23% of dual eligibles indicated any 
out-of-pocket spending in 2005. In addition, the distribution was skewed and over half of participants 
indicated out-of-pocket costs in the <$25 range in 2005. We also examined ADAP use, motivated by 
reported coordination between Medicare Part D and ADAP.
91
 Participants reported whether they used 
ADAP at each study visit. In these analyses, ADAP use was coded as a binary indicator for any use 
vs. none since the last study visit.  
ART adherence was coded as a binary variable, indicating either <100% or 100% adherence 
since last visit. In a sensitivity analysis, we also examined an alternative definition of adherence, 95% 
or greater vs. <95%. VL measurements were taken every six months using the NucliSens assay 
(Organon Teknika Corp.), which had a lower limit of detection of 80 copies/mL during the time period 
of this analysis. We defined viral suppression as HIV VL ≤200 copies/mL.
94
 Missing values for all 
outcome measures and covariates were carried forward from last available visit.  
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Statistical Analysis 
We explored the relationship between Medicare Part D and outcome variables using a 
segmented locally weighted smoothed spline (Lowess)
78
 to visualize trends for dual eligibles and 
Medicaid-only participants non-parametrically. We allowed for inflection points at Medicare Part D 
implementation on January 1, 2006, to visualize discontinuities associated with the transition. A 
Lowess plot fits a polynomial at each time point using weighted least squares, thus “smoothing” the 
outcome levels between data points.  
Propensity Score Matching 
We created a propensity score–matched cohort in which we matched dual eligibles with 
Medicaid-only participants. Under the assumption that the propensity score model was specified 
correctly, propensity scores should balance covariates between the two groups in the pre–Medicare 
Part D period, strengthening the assumption that the matched Medicaid-only group represents an 
appropriate counterfactual for dual eligibles had that group not transitioned to Medicare Part D. 
We used logistic regression to create propensity scores, with dual eligibility as the dependent 
variable and potential confounders as independent variables. We used a 1:1 nearest neighbor 
matching approach, without replacement, and dual eligibles were matched with the Medicaid-only 
participants with the propensity score that was nearest to their own. The covariate balance between 
dual eligibles and the matched control group was evaluated by comparing standard differences of 
means and t-test statistics between the two groups. We included baseline (pre–Medicare Part D) 
values for the following variables in the logistic regression models to create propensity scores: age at 
visit, race/ethnicity, education, employment, ADAP use, out-of-pocket prescription drug spending, and 
HIV VL. Continuous variables (age, VL) were included in the logistic regression as splines and 
categorical variables were dichotomized. We used the psmatch2 program in Stata (StataCorp, 
College Station, TX) to perform the 1:1 match.
95
 
We estimated the effects of Medicare Part D implementation on dual eligibles with HIV using 
a difference-in-difference (DiD) approach in a propensity score matched cohort. The DiD approach 
compares the average changes from pre– to post–Medicare Part D in dual eligibles, the group that 
was affected by the transition, to the average changes during the same time period in participants 
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with Medicaid only, a group unaffected by Medicare Part D. The resulting “difference-in-differences” 
can be attributed to the policy change if the assumption of parallel trends is met—the two groups can 
be balanced on baseline covariates—and there is sufficient overlap in the propensity scores between 
the matched groups. Linear regression was used to estimate the change in the proportion of 
participants experiencing outcomes of interest. Our Medicaid-only control group allowed us to 
estimate changes in the outcomes of dual eligibles while controlling for temporal trends (e.g., 
advances in ART). 
Finally, we performed several sensitivity analyses to test the assumptions inherent in 
propensity score matching and DiD analyses. We explored the parallel trends assumption using the 
Lowess plots, tested the balance of baseline covariates, and quantified propensity score overlap of 
the two matched groups. Sensitivity analyses included abbreviating pre– and post–Medicare Part D 
time periods (i.e., restricting to the 2004–2007 and 2005–2006 time periods) and specifying different 
sets of covariates in the propensity score model. All statistical analyses were performed using Stata 
13 (StataCorp, College Station, TX).  
Results 
A total of 801 women were included in this analysis, of which 125 (16%) were dual eligible 
and 676 (84%) had Medicaid only (Table 1). Median age of dual eligibles was higher than participants 
on Medicaid only (47; interquartile range [IQR]: 41, 52 vs. 43; IQR: 38, 49, respectively). Among dual 
eligible participants, 57% were African American compared to 68% of Medicaid-only participants. In 
2005, 10% of dual eligibles participated in ADAP compared to the 5% of Medicaid-only participants 
who participated in ADAP. A greater proportion of dual eligibles had completed high school or higher 
compared to Medicaid-only participants (76% vs. 48%); and a lower proportion of dual eligibles 
reported an annual household income of <$12,000 compared to those with Medicaid only (62% vs. 
67%). Finally, a greater proportion of dual eligibles were virally suppressed compared to Medicaid-
only participants (59% vs. 48%) despite similar reported ART use and ART adherence levels.  
Following Medicare Part D implementation, Lowess plots showed a sharp increase in out-of-
pocket prescription drug spending in 2006 (Figure 5a). Although reports of any out-of-pocket 
spending attenuated over the following two years, dual eligibles’ out-of-pocket spending did not return 
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to pre–Medicare Part D levels. Lowess plots showed a more gradual increase in ADAP use, 
compared to the sharp rise in out-of-pocket spending, among dual eligibles (Figure 5b). 
Lowess plots of ART adherence showed no inflection points for either group. Viral 
suppression appeared to be increasing over time in both groups, possibly corresponding to advances 
in ART, with no discontinuity following Medicare Part D implementation (Figure 5c-d). Lowess plots 
also indicated that the parallel trend assumption held for all outcomes of interest during the pre–
Medicare Part D time period, strengthening the validity of the DiD analyses. 
The set of variables used in the propensity score matching resulted in a covariate balance 
between the two groups on sociodemographics, medication use and related spending, and heath 
status (Table 3). Propensity score overlap was judged to be sufficient between the two groups. In the 
propensity-score matched DiD analyses, dual eligibles showed increases in out-of-pocket spending 
on prescription drugs, with 23% reporting any out-of-pocket spending for prescription drugs in the 
pre–Medicare Part D time period in contrast to 41% in the post–Medicare Part D time period (Table 4). 
Adjusting for any temporal trends by subtracting the change in the matched control group, the DiD 
estimate attributed to the transition to Medicare Part D was an average 20% change (95% CI: 12%–
27%) in proportion of dual eligibles reporting out-of-pocket spending. ADAP use increased by 10% 
among dual eligibles following Medicare Part D implementation (95% CI: 3%–18%).  
Levels of self-reported ART adherence were comparable in dual eligibles and Medicaid-only 
enrollees in the pre–Medicare Part D time period (47% vs. 39%) and in the post–Medicare Part D 
time period (48% vs. 44%), and DiD estimation did not attribute a significant change to the transition. 
Similarly, DiD estimation did not attribute a significant change in the proportion of dual eligibles who 
were virally suppressed, after adjusting for temporal trends.  
Discussion 
This is first study to examine the effects of Medicare Part D implementation on out-of-pocket 
prescription medication costs, ART adherence, viral suppression, and ADAP use among HIV-infected 
women enrolled in Medicaid and Medicare (dual eligibles). As anticipated, the proportion of dual 
eligibles reporting out-of-pocket spending for prescription drugs increased following Medicare Part D 
implementation. Despite this increase, ART adherence and viral suppression remained stable after 
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the transition to Medicare Part D. The proportion of dual eligibles using ADAP also increased in the 
Medicare Part D time period, though the increase was more gradual following the rise in out-of-pocket 
prescription drug spending. Taken together, these results suggest that although the transition to 
Medicare Part D was associated with increased self-reported out-of-pocket costs and ADAP use, 
ART adherence and viral suppression remained stable.  
Cost-Sharing and Out-of-Pocket Prescription Drug Spending 
Our findings differed from previous research that reported no change in dual eligibles’ out-of-
pocket prescription drug costs in either the transition or the stable period following Medicare Part D 
implementation.
96
 However, those study results were based on a sample of elderly dual eligibles, 
whose health needs differ from non-elderly HIV-infected populations. Our findings are supported by 
the one previous study of HIV-infected individuals, in which 60% of those enrolled in a Medicare Part 
D prescription drug plans reported increased out-of-pocket prescription drug expenditures shortly 
after implementation.
9
  
ADAP Use and Medicare Part D 
Lowess plots indicate an increase in ADAP use following the increase in out-of-pocket 
prescription drug spending. These findings are supported by reports of coordinated coverage of dual 
eligibles through Medicare Part D and ADAP.
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 It warrants noting that despite the rise in ADAP use 
and the financial advantages of using ADAP in combination with Medicare Part D, only 22% of dual 
eligibles in this study reported ADAP use and 41% still reported out-of-pocket prescription drug 
spending in 2008. 
ART Adherence and Viral Suppression 
Given reports of ART interruption and increased out-of-pocket prescription drug costs shortly 
after Medicare Part D implementation,
9,10
 we hypothesized that an increase in out-of-pocket 
prescription drug spending would lead to decreased ART adherence and, consequently, decreased 
VL suppression. However, we found that dual eligibles’ ART adherence remained stable over time. 
There are several explanations for consistent ART adherence. First, it is possible that increased 
enrollment in ADAP mitigated any effects of increased spending, resulting in stable ART adherence. 
Second, despite large increases in the proportion of dual eligibles with any out-of-pocket prescription 
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drug spending, the bulk of participants reported low out-of-pocket spending. For persons with out-of-
pocket costs, 54% of participants reported out-of-pocket costs ranging from $1-$25, and 42% of 
participants had out-of-pocket costs ranging from $26-$200 in the prior six months. Even though two-
thirds (66%) of the study population reported a household income <$12,000 per year, it is possible 
that the costs were not high enough to lead to cost-related nonadherence to ART. Finally, we also 
considered the possibility that the burden of out-of-pocket spending may have translated to also a 
reduction in spending on other essential needs (e.g., food, child care, housing, etc.) or that WIHS 
participants may have been more conscientious about their adherence due to their long-term 
involvement with the WIHS.  
Similarly, we also found no evidence of changes in VL suppression in dual eligibles 
associated with Medicare Part D. Though the proportion of dual eligibles who were virally suppressed 
increased between the pre– and post–Medicare Part D time periods, the increase was similar to the 
trend observed in the Medicaid-only comparison group, indicating that both groups benefit from 
improvements in ART. In the context of this study, those results suggest that the stability of viral 
suppression may be the result of increased use of ADAP rather than the result of improved 
medication access through Medicare Part D. This interpretation is supported by other studies, in 
which ADAP use was associated with an increased use of ART
97
 and increased likelihood of viral 
suppression.
98
  
Limitations 
Out-of-pocket costs, ART adherence, and ADAP use are self-reported in the WIHS over a 
period of six months, which may have led to misclassification or recall bias. Our study was also 
limited to dual-eligible women with HIV who participate in a longitudinal cohort study, and results may 
not be generalizable to all dual eligibles with HIV. Finally, propensity scores can only balance groups 
on measured covariates and, as in all observational studies, unmeasured covariates may confound 
our results. 
Despite these limitations, the outcomes have a unique advantage over claims and clinic data 
in that study visits occur at six-month intervals and are independent of insurance status or 
prescription fill behavior. This study has an additional advantage that it allowed us to study the effects 
39 
of Medicare Part D on a laboratory measure of viral load suppression, a key indicator of effective ART 
use.  
Conclusions 
Prior studies showed improved medication access following Medicare Part D implementation 
in many Medicare enrollees. However, dual eligible women with HIV, an understudied and medically 
vulnerable group, did not reflect those improvements in medication access or reduced out-of-pocket 
prescription drug costs seen in other Medicare enrollees. Our results underscore the importance of 
ADAP’s role in maintaining medication access and viral suppression during federally mandated 
insurance coverage transitions. Although ADAP is essential in providing HIV medications to those 
who have no insurance, the program also appears to benefit dual eligibles with HIV by reducing out-
of-pocket spending on prescription drugs.  
This study has implications beyond Medicare Part D and dual eligibles with HIV. Medicare 
Part D’s market-based, consumer-driven prescription drug plans are analogous to the privatized, 
market-based coverage that many people with HIV encounter through health insurance exchanges 
following the implementation of the Affordable Care Act (ACA). An additional similarity is that the ACA 
allows ADAP to provide similar wrap-around benefits for people with HIV as ADAP provided for dual 
eligibles under Medicare Part D, covering premiums and co-payments for prescription drugs. This 
study underscores that medication safety-net programs such as ADAP may be vital in ensuring 
smooth insurance coverage transitions, an important lesson as people with HIV transition to private 
prescription drug coverage under the ACA.  
 Table 3. Baseline Characteristics of Medicaid-Medicare Dual Eligibles and Medicaid-Only Participants, Aim 1, Women’s Interagency HIV Study 
(2005) 
 
 Unmatched sample (n=801)  Propensity score-matched sample (n=236) 
Dual Eligibles  
(n=125) 
Medicaid-only  
(n=676) 
p-value
a
  Dual Eligibles  
(n=118) 
Medicaid-only  
(n=118) 
p-value
a
 
        
Age in years, median 
(IQR)  
47 (41, 52) 43 (38, 49) 0.005  46 (41, 52) 46 (41, 52) 0.603 
African American, % 56.5 67.9 0.014  59.0 64.4 0.394 
Hispanic Ethnicity, % 24.2 26.6 0.575  23.9 23.7 0.971 
WIHS Site, %        
Bronx 15.2 28.7 0.002  16.1 23.7 0.144 
Brooklyn 20.0 23.5 0.391  20.3 16.9 0.506 
Washington, DC 08.0 08.6 0.831  08.5 11.9 0.391 
Los Angeles 20.0 11.0 0.005  19.5 15.3 0.393 
San Francisco 24.0 15.1 0.014  22.0 17.8 0.417 
Chicago 12.8 13.2 0.912  13.6 14.4 0.852 
ADAP 10.4 05.1 0.019  07.7 07.6 0.985 
Any out-of-pocket 
prescription spending, % 
22.8 12.9 0.004  21.6 14.5 0.165 
100% ART adherent
b 
51.2 43.2 0.127  51.2 48.4 0.719 
CES-D, median (IQR) 14 (3.5, 28.5) 15 (6, 25) 0.844  14 (3, 27) 15 (4, 27) 0.698 
Household income 
<$12,000/year, % 
62.1 67.1 0.278  62.2 60.9 0.849 
Graduated high school, % 76.4 48.1 <0.0001  25.5 27.0 0.792 
Employed, % 12.9 18.6 0.129  12.1 10.0 0.558 
CD4 cell count, median 
(IQR) 
466 (312, 643) 416 (249, 622) 0.265  484 (324, 658) 476 (316, 728) 0.396 
Virally Suppressed
c
, % 59.3 48.0 0.021  59.6 64.7 0.447 
Abbreviations: ADAP, AIDS Drug Assistance Programs; ART, antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale; IQR, 
interquartile range; HIV, Human Immunodeficiency Virus; WIHS, Women’s Interagency HIV Study 
a
 Statistical significance tested using t tests 
b
 Proportions calculated within subset of dual eligibles (n=103) and Medicaid-only participants (n=461) on ART 
c 
Viral suppression corresponds to a VL measurement of <200 copies/mL 
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 Table 4. Difference-in-Differences Estimates—Average Proportion Change in Pre- and Post-Medicare Part D Time Period, by Insurance Type, 
Women’s Interagency HIV Study 2003–2008, Aim 1 
 % with OOP spending   % Using ADAP  % ART adherent  % Virally suppressed 
 % SE p-value  % SE p-value  % SE p-value  % SE p-value 
Pre-Medicare Part D 
(2003-2005) 
               
Medicaid-only 0.23    0.13    0.39    -0.50   
Dual eligible 0.24    0.14    0.47    -0.55   
Difference 0.01 0.04 0.859  0.01 0.04 0.716  0.08 0.05 0.155  -0.05 0.05 0.361 
                
Post-Medicare Part D 
(2006-2008) 
               
Medicaid-only  0.21    0.10    0.44    -0.62   
Dual eligible  0.41    0.22    0.48    -0.66   
Difference 0.20 0.04 <0.001  0.12 0.04 0.004  0.04 0.05 0.440  -0.05 0.05 0.337 
                
Difference-in-Differences 0.20 0.04 <0.001  0.10 0.04 0.007  -0.04 0.05 0.440  -0.001 0.05 0.987 
Abbreviations: ADAP, AIDS Drug Assistance Program; ART, Antiretroviral Therapy; OOP, out-of-pocket; VL, viral load; SE, standard error 
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Abbreviations: ADAP, AIDS Drug Assistance Program; ART, Antiretroviral Therapy 
Figure 5. Change in proportion of outcome of interest, by insurance type and time period in the Women’s Interagency HIV Study (WIHS), 2002–2008, 
Aim 1.  
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CHAPTER 5: EFFECTS OF MEDICARE PART D ON MENTAL HEALTH TREATMENT AND 
OUTCOMES (AIM 2)  
The objective of Aim 2 was to estimate the effect of Medicare Part D on self-reported 
antidepressant use, depressive symptoms, and hospitalization among dual eligibles with HIV. We 
hypothesized that we would observe a decrease in antidepressant use among dual eligibles after 
Medicare Part D implementation and that this decrease would remain after adjusting for temporal 
trends using a matched control group of Medicaid-only participants. We further hypothesized that 
this disruption in antidepressant treatment would lead to an increase in depressive symptoms and 
hospitalization. 
Introduction 
Depression is the most common psychiatric comorbidity in people with HIV.
1
 Untreated 
depressive symptoms have been associated with reduced antiretroviral therapy (ART) 
adherence,
2–4
 unsuppressed HIV viral load,
5,6
 and shortened survival time.
7
 In turn, sub-optimal 
antiretroviral therapy (ART) adherence has been shown to increase the risk of hospitalization in 
women with HIV.
8
 By contrast, people with HIV who are treated for depression showed similar 
ART adherence and viral control to people with HIV who did not have depression,
9
 highlighting 
antidepressant use as a point of intervention with the potential to improve depression, 
hospitalization, and HIV outcomes.  
For many people with HIV, health insurance facilitates access to prescription drugs, such 
as antidepressants, that would be prohibitively expensive otherwise.
10
 Further, the majority of 
people with HIV rely on public insurance programs for medication access, with 56% receiving 
coverage through Medicaid or Medicare. Medicare provides health insurance to Americans age 
65 and over as well as to persons under the age of 65 with permanent disabilities.
11
 Medicaid 
programs have traditionally provided health insurance to certain categories of low-income 
persons. Of adults with HIV, 10% meet eligibility criteria for Medicare and Medicaid and are 
enrolled in both programs (referred to as “dual eligibles”).
12
 For dual eligibles, Medicare provides 
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primary coverage while Medicaid absorbs the remaining costs and can also provide primary 
coverage for services not available through Medicare.
13
  
Before 2006, Medicare did not include a prescription drug benefit and dual eligibles were 
covered under Medicaid’s prescription drug benefit. On January 1, 2006, Medicare implemented 
its own prescription drug benefit, Medicare Part D, and required dual eligibles to transition their 
prescription drug coverage from Medicaid to Medicare Part D.
14
 The goal of Medicare Part D was 
to improve medication access by reducing financial barriers for Medicare enrollees. Although a 
systematic review of Medicare Part D implementation and its effects on medication use indicated 
that Medicare Part D was associated with increased medication use and decreased out-of-pocket 
costs in the general Medicare population, the effects on dual eligibles and other vulnerable 
populations was mixed.
15
 In the transition to Medicare Part D, dual eligibles were enrolled in 
prescription drug plans that, within general guidelines, determined their own formularies and 
medication access rules, which often varied widely by plan. Further, cost-sharing for prescription 
drugs was mandated under Medicare Part D.
16
 By contrast, Medicaid’s prescription drug benefit 
had a broader benefits package, only allowed nominal cost-sharing,
17
 and included additional 
protections that allowed enrollees to receive their prescriptions without co-payment if they are 
unable to pay.
16
 
Cost-sharing and medication disruptions are a special concern for dual eligibles with 
mental health conditions because this population has a limited ability to pay for medications and 
disruptions can have rapid consequences for symptoms and health service use.
18
 Two studies 
examined the effects of Medicare Part D on dual eligibles with mental illness shortly after 
implementation.
19,20
 In the first study, psychiatrists indicated that 44% of their dually eligible 
patients had difficulties accessing a psychiatric medication shortly after Medicare Part D 
implementation. Of dual eligibles who had difficulty accessing medication, 22% had difficulty 
paying for their medications.
19
 The second study demonstrated that access problems for dual 
eligibles with psychiatric conditions did not decrease during the first year after Medicare Part D 
implementation but increased slightly instead.
20
 These studies indicate that Medicare Part D was 
associated with financial and administrative barriers to medication access for dual eligibles with 
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mental health conditions and that those barriers were sustained over at least the first year after 
implementation. 
Medicare Part D implementation has also been associated with psychiatric medication 
switching or discontinuation.
20,21
 Of dual eligibles with psychiatric conditions who reported 
difficulties accessing medication, 19% had to switch to a different drug
19
 and 29% discontinued or 
temporarily stopped their medication because of coverage limitations.
20
 Increased switching 
following Medicare Part D may adversely affect mental health outcomes because psychotropic 
drug classes are less therapeutically interchangeable than medications for other chronic 
conditions (e.g., nonsteroidal anti-inflammatory drugs).
22
 Prescription drug plans within Medicare 
have shown variable medication switching rates, indicating some plans may be more appropriate 
for dual eligibles with psychiatric conditions.
23
  
Given indications of increased cost-sharing, variation in prescription drug plan formularies, 
and reports of dual eligibles’ psychiatric medication disruption and discontinuation associated with 
Medicare Part D, the goal of this study was to estimate the effects of Medicare Part D on 
antidepressant use, changes in depressive symptoms, and subsequent risks for hospitalization 
among women with HIV. We used six years of data from a longitudinal cohort study—the 
Women’s Interagency HIV Study (WIHS), which investigates the long-term effects of HIV-infection 
and treatment in women.  
Methods 
Data Source 
The WIHS prospectively studies women who are HIV-infected and women at high risk for 
HIV infection enrolled at multiple U.S. study sites.
24,25
 Since its initiation in 1994, the WIHS has 
collected data on 3,398 HIV-infected women. We restricted our analyses to biannual WIHS visits 
between 2003 and 2008. During the timeframe of this study, the WIHS consisted of six study sites 
located in the Bronx, NY; Brooklyn, NY; Washington, DC; San Francisco, CA; Los Angeles, CA; 
and Chicago, IL. Study visits include a physical examination, survey questions, and laboratory 
measurements.  
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Design and Study Sample 
 We estimated the effects of Medicare Part D implementation on changes in outcomes of 
dual eligible participants while controlling for temporal trends using data from participants who 
received coverage through Medicaid only. Participants who missed three consecutive visits 
between 2003 and 2008 were administratively censored. We further restricted our study to 
participants who 1) were HIV-infected in 2003 and 2) reported Medicaid-Medicare dual eligibility 
or Medicaid-only enrollment in 2005 as indicators of their transition to Medicare Part D on 
January 1, 2006. There were 1,807 HIV-infected participants who attended study visits between 
2003 and 2008 and had not missed more than three consecutive visits in that timeframe. Of those, 
125 dual eligibles and 676 Medicaid-only participants met the inclusion criteria for this study.  
Measures 
Health Insurance Status  
Although dual eligibles were the focus of this study, we categorized participants into two 
mutually exclusive groups by insurance status. Participants who were dual eligibles at any point 
in 2005 were considered dual eligible at the transition to Medicare Part D and made up our 
analytic group of interest. Participants who reported Medicaid coverage and no other private or 
public insurance in 2005 were considered Medicaid-only at the transition to Medicare Part D and 
made up our matched control group. 
Outcomes of Interest 
We considered the following outcomes: 1) antidepressant use, 2) depressive symptoms, 
and 3) hospitalization.  
We examined pharmacologic treatment of depression by assessing the proportion of 
participants who self-reported antidepressant use since their last study visit, i.e., antidepressant 
use in the last six months. The binary indicator of any antidepressant use corresponded to a 
measure of use or nonuse of a prescribed medication with a primary indication for treating 
depression.  
Depressive symptoms were assessed at each WIHS visit using the Center for 
Epidemiologic Studies Depression Scale (CES-D).
26
 The instrument uses a 20-item scale in 
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which each item is rated on frequency of occurrence in the past seven days. Scores range from 0 
to 60. We also examined a binary indicator of “probable depression” where participants were 
classified as having probable depression if their CES-D score was 16 or more.
26
 We considered a 
third specification, a binary indicator of self-reported depression for which participants were asked 
assess whether they had several medical conditions, including depression, since the last study 
visit. 
Finally, we assessed inpatient hospitalization. Emergency room usage that did not result 
in hospital admission was not considered. In addition to the binary indicator of any hospitalization 
in the six-month interval since the previous study visit, we also assessed the number of 
hospitalizations.  
Statistical Analysis 
Before creating the propensity score matched cohort, we plotted outcome variables for 
visits from 2003 to 2008 using a segmented locally weighted smoothed spline (Lowess).
27
 
Lowess plots were created for each outcome to non-parametrically visualize pre– and post–
Medicare Part D trends for dual eligibles and Medicaid-only participants. The plots were 
segmented at Medicare Part D implementation on January 1, 2006, for both groups to visualize 
any discontinuities associated with the transition.   
Propensity score matching 
We used propensity scores to match dual eligibles with study participants who were 
enrolled in Medicaid only. The two groups were matched on propensity scores because it is 
possible that an unadjusted comparison between dual eligibles and the Medicaid-only could be 
confounded by differences inherent in the two groups. The goal of propensity score matching is to 
balance covariates between the two groups in the pre–Medicare Part D time period. Covariate 
balance strengthens the assumption that the matched control group represents the dual eligibles’ 
counterfactual outcomes. 
Propensity scores were created using logistic regression, where dual eligibility was a 
function of the pre-treatment covariates. After estimating the propensity scores, dual eligibles 
were matched 1:1 with Medicaid-only participants using a nearest-neighbor matching approach, 
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without replacement. Of the baseline (pre–Medicare Part D) variables considered for the 
propensity score model, our final set included: African American ethnicity, viral load, age, 
hospitalization, any psychotropic medication use, and total number of medications (ART and 
other). As continuous variables, age and viral load were included as splines, and categorical 
variables were dichotomized. Baseline values for time-varying variable were restricted to values 
from study visits in 2005. We used Stata’s psmatch2 program (StataCorp, College Station, TX) to 
match the groups by propensity score.
28
 
Finally, we used a difference-in-differences (DiD) approach on the propensity score 
matched cohort to estimate the effects of Medicare Part D implementation on dual eligibles with 
HIV. The Medicaid-only comparison group allowed us to control for temporal trends (e.g., 
advances in ART or antidepressants) that are common to both groups. The DiD approach 
consists of a linear model with an interaction term for insurance group (dual eligible or Medicaid-
only) and time period (pre– or post–Medicare Part D). The approach allowed us to compare the 
average changes in proportions between pre– and post–Medicare Part D in dual eligibles, the 
group that was affected by the implementation, to the average changes in proportions between 
pre– to post–Medicare Part D in participants with Medicaid only, the group that was unaffected by 
Medicare Part D. The resulting difference-in-differences can be attributed to the policy change if 
both groups have parallel trends in the pre–Medicare Part D time period, known as the parallel 
trends assumption.
29
  
Sensitivity analyses included examination of short-term and long-term effects of Medicare 
Part D by abbreviating pre– and post–Medicare Part D time periods (2004–2007, 2005–2006) as 
well as comparing propensity score model specifications and outcome variable definitions. All 
statistical analyses were performed using Stata 13 (StataCorp, College Station, TX).  
Results 
Eight hundred and one women met the inclusion criteria, of which 125 (16%) were dual 
eligibles and 676 (84%) were Medicaid-only (Table 5). Before propensity score matching, dual 
eligibles differed from Medicaid-only participants in age, ethnicity, education, WIHS site, out-of-
pocket prescription drug spending, antidepressant use, hospitalization, and viral suppression. The 
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median age of dual eligibles was higher (47; IQR: 41-52) compared to Medicaid-only participants 
(43; IQR: 38-49). Fewer dual eligibles were African American compared to participants who were 
Medicaid-only (57% vs. 68%). A greater proportion of dual eligibles completed high school or 
higher levels of education compared to Medicaid-only participants (74% vs. 48%). Annual 
household income was low overall and two-thirds of participants (66%) earned less than $12,000 
annually, where 21% earned less than $6,000 (result not shown). Despite their higher household 
income, education levels, and better viral suppression, a greater proportion of dual eligibles 
reported being hospitalized in the six months since their last visit (24%) compared to Medicaid-
only participants (17%). 
There was a striking difference in the levels of antidepressant use between dual eligibles 
and Medicaid-only participants in 2005. Over 38% of dual eligibles reported antidepressant use 
compared to 18% of Medicaid-only participants. This finding was more pronounced in dual 
eligibles with severe depressive symptoms (CESD ≥16), of whom 49% were on antidepressants 
compared to 25% of Medicaid-only participants with severe depressive symptoms (result not 
shown). Despite different levels of antidepressant use, dual eligibles and Medicaid-only 
participants had similar levels of depressive symptoms, and both groups had median CES-D 
scores of 14.  
Before matching on the propensity score, we created Lowess plots for all outcomes to 
visualize trend breaks associated with Medicare Part D and to provide graphical support for the 
parallel trend assumption (Figure 6a–c). None of the outcomes of interest showed obvious trend 
breaks at Medicare Part D implementation in 2006. Lowess plots indicated that the parallel trend 
assumption held for all outcomes of interest and supported the validity of the DiD analyses. After 
matching on the propensity score, our sample was limited to 117 dual eligibles (94% of the 125 
participants who were dual eligible in 2005) whose propensity scores were within the range of the 
propensity scores of the control group and a matched group of 117 Medicaid-only participants.  
Within the matched cohort, we estimated the DiD for all outcomes of interest and 
obtained the average change in proportion in dual eligibles between the two time periods, 
adjusted for temporal trends (Table 6). After accounting for temporal trends by subtracting the 
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effect in the matched control group, the implementation of Medicare Part D did not seem to have 
an impact on dual eligibles’ antidepressant use, depressive symptoms, or hospitalization.  
Discussion 
This study yielded several key findings. First, the unmatched, unadjusted comparison 
between dual eligibles and Medicaid-only participants showed that, in 2005, antidepressant use 
was significantly higher among dual eligibles than among participants with Medicaid only (38% vs. 
18%), despite similar levels of depressive symptoms. Further, a greater proportion of dual 
eligibles with severe depressive symptoms reported antidepressant use in 2005 compared to 
Medicaid-only participants with severe depressive symptoms (49% vs. 25%). However, both 
groups received prescription drug coverage through Medicaid in 2005, making it unlikely that 
prescription drug coverage characteristics (formularies, utilization management tools, etc.) are 
responsible for this difference in antidepressant use.  
Under conditions that effectively hold prescription drug coverage constant between the 
two groups, there are several possible explanations for these findings. First, there are several 
other differences between dual eligibles and Medicaid-only enrollees in 2005 (age, ethnicity, 
education, hospitalization, viral suppression, and WIHS site). However, the association between 
insurance type and antidepressant use remained after adjustment for the variables mentioned. 
Second, people with psychotropic medication needs may be more likely to become Medicare 
enrollees through mental health–related disability. Third, although dual eligibles received 
prescription drug coverage through Medicaid before 2006, they were still receiving medical 
coverage through Medicare. Dual eligibles may have been able to access medical care more 
easily than Medicaid enrollees, and access to care, rather than prescription drug coverage, may 
determine antidepressant use. This interpretation is supported by studies showing that 
Medicare’s provider reimbursements were 39% higher than Medicaid’s provider reimbursements 
and that providers were more likely to accept new patients who were Medicare enrollees 
compared to Medicaid enrollees.
30,31
  
The DiD analyses indicated that Medicare Part D implementation did not affect 
antidepressant use in dual eligibles despite the program’s mandatory cost-sharing. Although 
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antidepressant use did not appear to be disrupted by Medicare Part D implementation, it is 
possible that Medicare Part D drug plans led to enrollees to switch to less effective 
antidepressants. Prior Medicare Part D research indicated that of dual eligibles had difficulty 
accessing a psychiatric medication following Medicare Part D, 19% were switched to a different 
drug because their prescribed medication was either not covered or not approved.
32
  
Despite prior evidence of potentially sub-optimal medication switching, our analyses also 
did not detect a change in depressive symptoms. Depressive symptoms remained stable in both 
groups throughout the study period. Finally, dual eligibles showed no change in hospitalization 
following Medicare Part D—the proportion of dual eligibles being admitted to the hospital over a 
six-month time period remained approximately 20% both before and after Medicare Part D 
implementation.  
Limitations 
WIHS does not collect data on insurance characteristics and we were unable to examine 
specific characteristics of Medicare Part D prescription drug plans, such as use of utilization 
management tools for antidepressants.
34
 It is possible that study visits occurring at six-month 
intervals are too far apart to detect acute disruptive effects, as identified in prior studies on 
medication access. However, given the periodic timing of the WIHS data collection, these findings 
indicate that Medicare Part D did not have a sustained, long-term effect on antidepressant use, 
depressive symptoms, or hospitalization. Finally, all WIHS participants are women and dual 
eligible women may have distinct patterns of antidepressant use, depression, and health service 
use that limit generalizability. Despite these limitations, this study has the advantage that data are 
collected independently of insurance status, medical care engagement, or prescription fill 
behavior. These data are a valuable resource for studying medication access problems because 
claims data may selectively represent people who successfully fill medications.  
Conclusions 
Coordinating care and managing costs for dual eligible eligibles is a vital health policy 
issue. This study highlights key differences between dual eligibles and Medicaid enrollees and 
adds to the limited body of knowledge on how transitioning prescription drug coverage from 
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Medicaid to Medicare Part D affects mental health and related service use. We found that while 
receiving the same prescription drug coverage through Medicaid in 2005, a greater proportion of 
dual eligibles used antidepressants compared to Medicaid-only participants, despite similar levels 
of depressive symptoms. Although prior research of Medicare Part D and dual eligibles with HIV 
indicated difficulty accessing medications after the transition
33
 we identified no such effect on 
antidepressant use. This analysis also identified no changes in depressive symptoms or 
hospitalization following Medicare Part D implementation. These findings may indicate that 
protections for psychotropic drug classes under Medicare Part D were meeting their intended 
function in this vulnerable population several years after implementation. Stable medication use 
may also be due to better access to medical care for dual eligibles through Medicare both before 
and after Medicare Part D implementation, which may eclipse any effects of the transition in 
prescription drug coverage. 
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Table 5. Baseline Characteristics of Medicaid-Medicare Dual Eligibles and Medicaid-Only 
Participants, Women’s Interagency HIV Study (2005), Aim 2 
 
Unmatched sample (n = 801)  
Propensity score matched sample (n 
= 234) 
Dual 
Eligibles  
(n = 125) 
Medicaid-
only  
(n = 676) 
P 
value
a
 
 Dual 
Eligibles  
(n = 117) 
Medicaid-
only  
(n = 117) 
P 
value
a
 
Age, median (IQR)  47 (41, 52) 43 (38, 49) <0.000  46 (41, 52) 46 (41, 51) 0.794 
African American, % 56.5 67.9 0.014  59.4 59.4 1.000 
Hispanic 
Ethnicity, % 
24.2 26.6 0.575  23.2 31.0 0.146 
WIHS Site, %        
Bronx 15.2 28.7 0.002  15.3 40.2 0.000 
Brooklyn 20.0 23.5 0.391  22.4 19.7 0.747 
Washington, DC 8.0 8.6 0.831  7.7 5.1 0.426 
Los Angeles 20.0 11.0 0.005  18.8 7.7 0.012 
San Francisco 24.0 15.1 0.014  23.1 15.4 0.137 
Chicago 12.8 13.2 0.912  13.7 12.0 0.672 
Out-of-pocket Rx 
spending 
22.8 12.9 0.004  22.6 14.8 0.129 
100% ART 
adherent
b 
51.2 43.2 0.127  52.6 48.4 0.563 
Antidepressant 
use, % 
38.2 18.4 0.000  37.6 35.9 0.787 
CES-D score, 
median (IQR) 
14 (3.5, 
28.5) 
15 (6, 25) 0.844  14 (6, 24) 14 (4, 29) 0.845 
Hospitalized, % 23.5 17.2 0.020  19.7 17.9 0.739 
Income 
<$12,000/year, % 
62.4 67.1 0.324  62.9 70.0 0.286 
Education, %        
Less than high 
school 
25.6 51.9 <0.000  25.0 23.3 0.760 
Employed, % 12.9 18.6 0.129  11.2 12.9 0.687 
Lowest observed 
CD4, median (IQR) 
466 (312, 
643) 
416 (249, 
622) 
0.265  422 (291, 
643) 
452 (279, 
644) 
0.894 
Suppressed HIV VL
c 
59.3 48.0 0.021  56.5 60.9 0.505 
 
Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; IQR, inter-quartile range; HIV, 
Human Immunodeficiency Virus 
a
 Statistical significance tested using t tests 
b
 Proportions calculated within subset on ART 
c 
Suppressed HIV VL corresponds to a viral load measurement of <200 copies/mL 
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Table 6. Difference-in-Differences Estimates – Average Proportion Change in Pre- and Post-
Medicare Part D Time Period, by Insurance Type, Women’s Interagency HIV Study 2003-2008, 
Aim 2 
 
Antidepressant Use 
 Severe Depressive 
Symptoms (CESD ≥ 
16) 
 
Hospitalization 
 
% SE 
p-
value 
 
% SE 
p-
value 
 
% SE 
p-
value 
Pre-Part Medicare 
Part D 
           
Medicaid-only 26.3    44.2    19.4   
Dual eligible 33.2    48.0    19.4   
Difference +7.0 0.05 0.133  +3.8 0.0
5 
0.456  +0.0 0.03 0.992 
            
Post-Part Medicare 
Part D 
           
Medicaid-only  32.8    43.4    19.9   
Dual eligible  36.1    46.2    20.6   
Difference +3.4 0.05 0.505  +2.8 0.0
5 
0.579  +0.8 0.03 0.811 
            
Difference-in-
Differences 
-3.6 0.04 0.367  -1.0 0.0
4 
0.786  +0.8 0.03 0.805 
Abbreviations: CESD, Center for Epidemiologic Studies Depression Scale; SE, Standard Error  
 
 
 
  
  
                          
 
Figure 6. Change in proportion of outcome of interest, by insurance type, time period in the Women’s Interagency HIV Study (WIHS), 2002–2008, 
Aim 2
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CHAPTER 6: DISCUSSION 
 Medicare Part D is a federally funded, privately administered prescription drug benefit 
implemented on January 1, 2006. The goal of Medicare Part D was to improve medication access 
by reducing financial barriers for Medicare enrollees, many of whom did not have prescription 
drug coverage before 2006. For many enrollees over the age of 65, Medicare Part D 
implementation was associated with improved access to medication and lower OOP costs;
42–44
 
however, its effects on dual eligibles and other vulnerable populations was mixed.
61
 Few studies 
have examined the effects of Medicare Part D on dual eligibles with HIV.
9,10
 This was the first 
study to examine the effects of Medicare Part D implementation on OOP prescription medication 
costs, ADAP use, ART adherence, and viral suppression among dual eligibles with HIV. 
This dissertation produced several key findings. First, our results indicate that the 
proportion of dual eligibles with OOP prescription drug spending increased dramatically following 
Medicare Part D and that the increase was sustained in the years following Medicare Part D 
implementation. However, although the proportion of dual eligibles with OOP prescription drug 
spending appeared to increase, levels of medication use (ART adherence and proportion using 
antidepressants) remained stable. These findings are consistent with previous work showing no 
improvement in medication access in nonelderly disabled and depressed Medicare beneficiaries 
after Medicare Part D
60,111,65
 which contrasted with gains in medication use and reductions in 
OOP costs seen in elderly Medicare-only enrollees.
42–44
 In addition, our findings lend support to 
the previous study that indicated cost-related access problems for people with HIV following 
Medicare Part D implementation.
9
  
Second, the combination of stable medication use (both ART adherence and 
antidepressant use) and the increased proportion of dual eligibles using ADAP use may indicate 
that the potential impact of increased OOP costs on medication use were mitigated by ADAP use. 
This interpretation is supported by the temporal order of the changes in spending and ADAP: The 
immediate increase in the proportion of dual eligibles reporting OOP prescription drug spending 
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was followed by a more gradual increase in the proportion of dual eligibles reporting ADAP use. 
In addition to providing people with HIV with access to ART, many ADAP formularies, which vary 
by state, also provide people with HIV with medications such as antidepressants, to treat 
common comorbidities.
27
 As such, the increase in ADAP use stood to stabilize both ART 
adherence and antidepressant use.  
Further, despite the rise in ADAP use and the financial advantages of using ADAP in 
combination with Medicare Part D, only 22% of dual eligibles in this study reported ADAP use in 
the post–Medicare Part D time period while 41% still reported OOP prescription drug spending. 
This discrepancy, combined with the very low income of this study population, is indicative that 
many dual eligibles with HIV are not making full use of ADAP benefits available to them despite 
coordination and co-financing between ADAP and Medicare Part D.  
One of the most notable advantages of the data source used in this dissertation, 
compared to data used for prior Medicare Part D research is the inclusion of regularly collected 
laboratory measurements of HIV VL. Most Medicare Part D studies are limited to claims data or 
cross-sectional survey data and do not include laboratory measures. Though viral suppression 
increased in both groups over time, there was no difference in the proportions of dual eligibles 
who were virally suppressed associated with Medicare Part D. Given the stable medication use 
observed in both Aims 1 and 2, stable depressive symptoms and hospitalization levels over both 
time periods were in line with our other findings.  
Differences Between Dual Eligibles and Medicaid-Only Participants 
Our descriptive analyses in Aim 2 showed several differences between the two groups in 
the pre–Medicare Part D time period. First, the unmatched, unadjusted comparison between dual 
eligibles and Medicaid-only participants showed that, in 2005, antidepressant use was 
significantly higher among dual eligibles than among participants with Medicaid only (38% vs. 
18%) despite similar levels of depressive symptoms. This result is striking because the two 
groups both received prescription drug coverage through Medicaid in the pre–Medicare Part D 
time period and had similar levels of depressive symptoms. The discrepancy was similar but 
more exaggerated in dual eligibles with severe depressive symptoms (CESD>=16) who reported 
antidepressant use in 2005, compared to Medicaid-only participants with severe depressive 
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symptoms (49% vs. 25%). In exploratory analyses, antidepressant use remained significantly 
different between the two groups even after adjustment for other baseline differences. It is 
possible that people with HIV and mental health conditions may be more likely to become dual 
eligible through disability. It is also possible that medical care, rather than prescription drug 
coverage, is a stronger determinant of access to antidepressants, would explain our finding, given 
higher provider reimbursements from Medicare compared to Medicaid.
107,108
  
Limitations 
There are several limitations of these data and this study. First, most outcomes were self-
reported in the WIHS over approximately six months, which may have led to misclassification or 
recall bias. Second, because the WIHS is a study of HIV-infected and -uninfected women, these 
results are limited to dual eligible women with HIV. Further, the dual eligible women in the WIHS 
are participants in a long-running HIV cohort study that may be associated with better care 
engagement and medication adherence compared to dual eligible women who are not 
participants in longitudinal cohort studies.  
Though our use of propensity score allowed us to achieve covariate balance between the 
two groups, and we were able to quantify the degree of common support between the two groups, 
we were only able to match the two groups on measured covariates. As in all observational 
studies, unmeasured covariates may still confound our study results. We were also limited in the 
number of covariates that we could use to estimate the propensity scores due to the small sample 
size of dual eligibles.  
Implications for Policy and Research 
Implications for ADAP 
This study has several implications for ADAP policy and research. First, findings from this 
study provide evidence for coordination between Medicare Part D and ADAP, previously 
indicated in reports on people with HIV and ADAP use around the time of Medicare Part D 
implementation.
27
 In the context of other study results, the combination of increased out-of-pocket 
costs and stable medication may be due to the stabilizing effects of ADAP on dual eligibles with 
HIV who are transitioning to Medicare Part D. If ADAP does mitigate Medicare Part D cost-
sharing, the coordination between Medicare Part D and ADAP may contribute to stable health 
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outcomes for people with HIV who transition to Medicare Part D and underscores the benefits of 
coordinated functioning between Medicare Part D and ADAP for people with HIV.  
Second, the ADAP budget has historically been used to purchase and provide 
prescription drugs directly to people with HIV, however ADAP’s role has been shifting to co-
financing insurance coverage in recent years. In 2011, $1.5 billion of the ADAP budget was 
dedicated to direct provision of prescription drugs and providing medications to ADAP clients 
made up 79% of ADAP expenditures.
58
 By contrast, only 16% of ADAP expenditures went 
towards insurance premiums, deductibles, and co-payments in that year. The coordination 
between ADAP and Medicare Part D at implementation was a demonstration of ADAP’s shifting 
role from direct provision of prescription drugs to ADAP covering Medicare Part D prescription 
drug co-payments. Our findings indicate that Medicare Part D did result in an increased use of 
ADAP and support the need for future studies on whether that increase stabilizes medication use 
by mitigating OOP spending for dual eligibles with HIV. As the role of ADAP continues to develop, 
this study provides evidence of increased ADAP use after Medicare Part D implementation when 
ADAP shifted from direct provision of medication to co-financing dual eligibles’ medication access 
in combination with a primary payer such as Medicare Part D. These coordinated efforts may 
have safeguarded this vulnerable population from medication disruption in the initial transition to 
Medicare Part D and may continue to mitigate the effects of cost-sharing for the people with HIV 
who have enrolled in Medicare Part D since 2006. 
Implications for Medicare Part D 
 Although our findings are restricted to Medicare Part D implementation in 2006, these 
results may generalize to people with HIV who are transitioning from being Medicaid-only to being 
dual eligible at any point after 2006. Since implementation of Medicare Part D, when people with 
HIV covered by Medicaid only eventually meet the eligibility criteria for Medicare, they become 
dual eligible, lose their prescription drug coverage through Medicaid, and are enrolled in Medicare 
Part D. In other words, this study examined a transition that happened to all dual eligibles with 
HIV in 2006, but individuals with HIV continue to experience that same transition as they become 
eligible for Medicare on top of their Medicaid enrollment in the years following Medicare Part D 
implementation. If these findings extend beyond the initial implementation in 2006 and generalize 
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to all transitioning dual eligibles, they indicate that dual eligibles may be relying on programs 
outside of Medicare Part D to maintain stable medication access and reduce the sudden increase 
in OOP costs that they experience.  
Implications for the ACA  
 Following the implementation of the ACA in 2014, many people with HIV are using health 
insurance exchanges to gain insurance coverage. Health insurance exchanges share several key 
similarities with Medicare Part D. Both are instances in which the federal government contracts 
with private insurance plans, where the federal government sets general standards that plans 
must adhere to but within those guidelines can vary widely on cost-sharing and utilization 
management strategies. Both health insurance exchanges and Medicare Part D provide a range 
of plans under the assumption that consumers select prescription drug plans that maximize 
access to needed services and minimize costs. An additional, crucial similarity is that the ACA 
allows ADAP to provide similar wraparound benefits for people with HIV as ADAP provided for 
dual eligibles under Medicare Part D, covering premiums and co-payments for prescription drugs. 
Given the similarities between the two avenues to accessing insurance coverage, our findings 
highlight the importance of ADAP during coverage transitions and indicate an advantage to 
coordination and co-financing with ADAP.  
Research Implications 
In addition to implications for policy, this study has implications for future research on dual 
eligibles. First, this study was limited to the 2006 transition of dual eligibles, and future studies 
should move beyond studying Medicare Part D implementation by examining the effects of the 
transition from Medicaid to Medicare Part D when Medicaid-only participants become dual eligible 
at any point in time after 2006. In other words, instead of examining the transition of all dual 
eligibles from Medicaid to Medicare Part D, future studies would examine that same transition in 
individuals as they move from being enrolled in Medicaid-only to being dual eligible after 2006 
and, consequently, move from prescription drug coverage through Medicaid to prescription drug 
coverage through Medicare Part D. By examining transitioning individuals after Medicare Part D 
implementation, these studies will be able to triangulate the effects of prescription drug coverage 
versus medical and prescription drug coverage because the transitioning population will receive 
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both prescription drug coverage and medical coverage through Medicaid pre-transition, unlike the 
dual eligibles in this study, who received prescription drug coverage through Medicaid and 
medical coverage through Medicare in the pre–Medicare Part D time period. Longitudinal WIHS 
data collection in the WIHS lends itself well to the study of individual transitions from one 
insurance type to another because study visits occur at six-month intervals and the same 
individuals are followed over time.  
Second, descriptive findings in this study revealed interesting discrepancies between the 
prevalence of antidepressant use among dual eligibles compared to Medicaid-only enrollees, 
despite similar levels of depressive symptoms. Further research examining the relationship 
between dual eligibility and Medicaid-only coverage over time may shed light on the associations 
between coverage type and access to psychotropic medications. The WIHS’ longitudinal data 
also allows for a more nuanced exploration of the differences in antidepressant use between HIV-
infected dual eligibles and Medicaid-only enrollees, which we observed in the pre–Medicare Part 
D time period in Aim 2. Building off of this study, we plan to examine differential antidepressant 
use in the pre–Medicare Part D time period, when both Medicaid-only and dual eligibles received 
prescription drug coverage through Medicare. We will explore the temporal relationships between 
insurance coverage, antidepressant use, and depressive symptoms, restricting to WIHS visits 
before 2006 and focusing on dual eligibles and Medicaid-only participants.  
Conclusion 
Our findings show an increase in the proportion of dual eligibles with HIV reporting out-of-
pocket costs following the implementation of Medicare Part D. The increase in costs was 
sustained over several years following implementation. In addition to an increased proportion of 
dual eligibles reporting out-of-pocket costs, dual eligibles also reported increase ADAP use, 
pointing toward coordination between Medicare Part D and ADAP. However, medication use, 
health outcomes, and health service use were stable following Medicare Part D implantation. 
Although there are several possible interpretations for increased costs and stable medication use 
and health outcomes, the increase in ADAP use underscores that safety-net programs such as 
ADAP may be vital in ensuring continuous coverage of both ART and antidepressants following 
insurance transitions, as OOP costs can be affected by policy changes. The protective feature of 
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ADAP covering medication copayments, and its apparent coordination with Medicare Part D may 
be applicable to people with HIV as they transition from Medicaid to private prescription drug 
coverage using health insurance exchanges. 
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